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INNATE IMMUNITY TOWARDS PATHOGENS 
The innate immune system provides a first line of host defense against many 
microorganisms as diverse as bacteria, fungi, mycobacteria, RNA and DNA viruses, 
protozoans… It is essential for the control of common bacterial infections since 
survival of the host organism depends on a rapidly mounted defense. The cells of the 
innate immune system, usually include macrophages and neutrophils but the 
epithelial cells, as the first physical barrier, is also involved in an innate immune 
response. 
Unlike adaptive immunity which is based on millions of lymphoid cell-surface 
receptors (generated by complex gene rearrangements) that recognize an infinite 
variety of antigens and capable of memory, the innate immune system is a non-
specific immune response based on a much smaller number of receptor called 
pattern recognition receptors (PRRs). 
PRRs can recognize conserved molecular pattern of a wide range of foreign 
organisms [1]. However, it can distinguish between pathogens and self. Such 
pathogen-associated molecular patterns (PAMPs) represent molecules vital for 
microbial survival and are therefore unlikely to vary in their structures because any 
major change would be disadvantageous. Such molecules include viral nucleic acids, 
components of bacterial and fungal cell walls (lipopolysaccharide LPS, 
peptidoglycans PGNs …) , flagellar proteins…  
Importantly, this system can also be activated by a variety of normal host proteins 
and danger signals that are released by cells and then are inappropriately localised 
[2], [3]. This system is tightly regulated and activated pathways are interconnected to 
avoid aberrant activation encountered in various autoimmune and inflammatory 
diseases [2]. 
The activation of PRRs can lead to mobilization of soluble defense molecules, killing 
of the infected cells or tissues, acquisition of specialized functions by sentinel cells, 
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induction of co-stimulatory molecules by antigen-presenting cells, switching on 
adaptative immunity and many other physiological responses. consequence of PRRs 
activation is transcriptional gene activation (nuclear factor-κB (NF-κB) or interferon-β 
(IFN-β) pathway), resulting in mobilization of the effectors of inflammation and cell 
survival. 
TLRs 
The first family of PRRs studied in details was the Toll-like receptor (TLR) family [4]. 
TLRs are classical transmembrane proteins with a ligand-binding domains composed 
of leucine-rich repeats (LRRs) that point towards the extracellular milieu or to the 
topologically equivalent lumen of membrane-enclosed intracellular compartments [5] 
(Fig.1). Thus, TLRs survey the extracellular fluids and endosomal compartment that 
can encapsidate foreign organisms. 
The TLR signal transduction domains, known as Toll/IL-1 receptor (TIR) domains, are 
directed towards the cytoplasm and transduce their signal through interactions with 
other adaptor proteins, which also contain a TIR domain for homotypic 
oligomerization [5] (Fig.1). 
This involves the myeloid differentation primary response protein (MyD)88, MyD88 
adaptor-like TIR domain containing adaptor inducing IFN-β (TRIF) and TRIF-related 
adaptor molecule (TRAM) [6] (Fig.1). TLR stimulation results in the activation of 
different intracellular signaling cascades, generally resulting in the activation of NF-
κB, mitogen activated protein (MAP) kinases and activating protein-1 (AP-1) in 
MyD88-dependant pathways and the activation of type I interferons (IFNs) in TRIF-
dependent anti-viral pathways [7] (Fig.1). 
TLRs are key inducers of the synthesis of the pro-forms of interleukins (IL)-1β and IL-
18; this is called “priming” the system for caspase-1, the enzyme proteolytically 
activating the pro-forms of IL-1β and IL-18 [8]. After activation of caspase-1 and 
extracellular release, both cytokines signal through their cognate receptors (IL-1 
receptor type I and IL-18 receptor), which, similarly to the TLRs, possess an 
intracellular TIR domain. IL-1β and IL-18 also use MyD88 to mediate their 
intracellular signaling effects [9]. 
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Two other families of PRRs has been described up to now: the NLRs (Nod-like 
receptors) and the RIG-like helicases (RIGs). Unlike TLRs, these families consist of 
soluble proteins that survey the cytoplasm for signs of pathogens or danger. 
RIG 
TLR3, TLR7, TLR8 and TLR9 are expressed in dendritic-cell (DC) populations and 
recognize different types of virally derived nucleic acids in endosomal compartments, 
activating signaling cascades that result in the induction of type I IFNs [10]. Although 
the importance of anti-viral TLRs in DC populations is well known, the key viral 
sensors in various cells other than DCs seem to be the RLRs (RIG-I like receptors) 
[11]. Retinoic acid inducible gene-1 (RIG-I) and melanoma differentiation-associated 
gene (MDA)5, which are intracellular sensors of double-stranded (ds)RNA, are two 
members of the RLR family [12], [13]. The RLR family show similarities with the anti-
viral TLRs in terms of signal activation (NF-κB and interferon-regulated factor-3, 
IRF3) and genes induced (type I IFNs), and also with Nod-like recptors NLRs (see 
later) because both NLRs and RLRs contain caspase recruitment domains (CARD) 
 
Figure 1: Toll-like receptor signaling pathways. 
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domains. In addition to two protein interaction CARD domains, RIG-I has an RNA 
helicase catalytic domain, which bind to viral RNA and recognize intracellular 
ribonucleoprotein complex (Fig.2). 
Following activation, these RLRs signal downstream through their CARD domains to 
a CARD-containing adaptor protein, IFNβ promoter stimulator (IPS)-1, ultimately 
resulting in IRF3 phosphorylation and NF-κB activation [14] (Fig.2). The RLRs are 
widely expressed and become upregulated following IFN-α/β activation. In contrast to 
anti-viral TLRs, which detect various types of viral infection, largely in DCs, the RLRs 
protect all virally infected cells. RIG-I plays an essential role in recognizing RNA 
viruses such as vesicular stomatitis virus (VSV) and Sendai virus (SV) [11], [15].  
MDA5 is required for picornavirus detection and polyinosine polycytidylic acid-
induced IFN-α production [16].  
Finally, it is likely that TLRs and RLRs, like TLRs and NLRs, function together to 
provide ubiquitous anti-viral protection, with anti-viral TLRs being more restricted to 
DCs. 
 
The last family of PRRs is the cytoplasmic NLRs. 
 
Figure 2: RLR signaling pathways. 
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NLR 
NLRs contain three distinct domains: an amino-terminal caspase recruitment domain 
CARD or pyrin effector domain PYD (with the exception of the neuronal apoptosis 
inhibitor protein NAIP, which is an inhibitor of caspases), a nucleotide-binding and 
self-oligomerisation domain NACHT domain (or domain present in NAIP, CIITA, HET-
E, TP-1) and a variable number of carboxy-terminal LRRs [17] (Fig. 3). This N-
terminus domain is an effector domain, regulating homotypic or heterotypic binding. 
Similar to TLR, the LRR are implicated in ligand binding and auto-regulation. The 
overall domain structure of this family suggests that these proteins can assemble into 
higher-order complexes. 
 
NLRs comprise two large sub-classes, the CARD-containing nucleotides 
oligomerization domain NODs (NOD1-5) and 14 members of the PYD-containing 
NALP (NACHT-LRR-PYD-containing protein) group NALP (Fig. 3). With ICE-protease 
activating factor (IPAF), NAIP and CARD-containing CIITA group of proteins, a total 
number of 22 NLR members have been identified so far [17] (Fig. 3). 
The biological significance of most of the NLRs remains to be determined. 
Nevertheless, some of them seem to be functionally important in the regulation and 
activation of pro-inflammatory caspases [18]. 
LR
RLigand binding and
auto-regulation
Self-olgomerization
Effector domain
 
modified from Martinon et al. Trends in Immunol. (2005) 
Figure 3: Domain organization of the members of the NLR 
family. 
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The PYD and CARD domains of NALPs and NODs normally link the receptor to 
downstream adaptor and effector proteins, such as receptor interacting protein (RIP)-
kinases or initiator caspases, through homotypic interactions connecting PYD-PYD or 
CARD-CARD.  
 
NLRs are synthesized in an 
inactive autorepressed form. 
Their LRRs domain is folded 
back onto the NACHT domain, 
thereby blocking the 
spontaneous NACHT-mediated 
oligomerization and subsequent 
activation of the NLR (Fig. 4). In 
the presence of a PAMP or 
danger signal, the molecule 
undergoes a conformational 
change exhibiting the NACHT 
domain thus triggering the 
oligomerization (Fig. 4). Through 
a homotypic interaction, CARDs and PYDs recruit CARD- and PYD- containing 
effector molecules, bringing them in close proximity and allowing their activation. 
The NOD subfamily 
The first NLRs reported to be intracellular microbial sensors were NOD1 and NOD2 
[19], [20]. They detect a small part of bacterial peptidoglycan (PGN). The ligand of 
NOD1 is the PGN component: D-γ-glutamyl-meso-diaminopimelate (mDAP) and the 
one of the NOD2 muramyl dipeptide (MDP) [21], [22]. 
NOD1 and NOD2 activate NF-κB through the recruitment and oligomerization of the 
inflammatory kinase RIP-2, via their homologue CARD domains. This results in the 
activation of inhibitors of NF-κB (IκB) kinase complex, subsequently releasing the 
NF-κB from the IκB complex and allowing it to translocate into the nucleus [23], [20] 
[24].  
 modified from Martinon et al. Trends in Immunol. (2005) 
DF:  Death domain, represent here the 
effector domain. 
 Figure 4: Mechanism of NLR activation. 
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NALPs and the inflammasome 
Up to now 14 NALPs has been identified in human [25]. Only few NALPs have been 
well characterized but a common feature is the presence a N-terminal pyrin effector 
domain. To date, the NLRs NALP1, NALP2, NALP3, NALP6 and NALP12 have been 
implicated in recruiting the adaptor protein ASC, apoptosis-associated speck-like 
protein containing a CARD, for activating caspase-1 complexes, the inflammasomes 
[26], [27], [28]. ASC consists of a CARD domain at its C-terminus and a PYD at its N-
terminus, making a bi-partite adaptor molecule involved in recruiting caspase-1 into 
activation complexes. Through a homotypic PYD-PYD interaction ASC bind to 
NALPs, which in turn binds to caspase-1 through a CARD-CARD interaction [26]. 
The oligomerization of NALPs brings into close proximity the inflammatory caspases, 
leading to their activation within the inflammasome [27]. 
Following stimulation, NALP1 assembles an inflammasome complex consisting of 
NALP1, ASC, caspase-1 and caspase-5 [27] (Fig. 5). The physiological stimulus for 
its activation is still unknown. However, the mechanical rupture of human monocytic 
leukaemia THP-1 cells is sufficient to activate inflammasome assembly [27]. NALP1 
is the only family member containing a F-interacting domain (FIIND) followed by a C-
terminal CARD domain (Fig. 5). Through the CARD domain, NALP1 can directly bind 
to caspase-5 (Fig. 5). 
The NALP2/3 inflammasome contains NALP2 or NALP3, CARDINAL, ASC and the 
caspase-1 but not the caspase-5 [29] (Fig. 6). NALP2/3 is devoid of both FIIND and 
CARD domains present in NALP1. Thus, a protein containing these specific C-
terminal domains CARDINAL is involved in linking the NALP2/3 to one molecule of 
caspase-1. The second molecule of caspase-1 is linked to the NALP2/3 by ASC 
adaptator (Fig. 6). 
NAD: NACHT-associated domain 
Figure 5: NALP1 inflammasome. 
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Thus, in contrast to NALP1 inflammasome, the NALP2/3 inflammasome activates 
only caspase-1. 
These inflammasomes are activated by extracellular adenosine triphosphate (ATP) 
and hypotonic stress, both of which are thought to mimic endogenous danger signals 
[30], [28], [27]. ATP functions by activating the P2X7 receptor, decreasing intracellular 
potassium K+ levels, which is confirmed by the observation that the K+ ionophore, 
nigerincin, has the same effect [31], [32]. Very recently, the NALP3 inflammasome 
has been convincingly shown to be activated by several stimuli, namely bacterial 
RNA, bacterial toxins (such as maitotoxin, α-toxin from S. aureus, listeriolysin O…) 
and ATP, and uric acid crystals [31], [32], [33]. NALP3 and ASC are also required for 
caspase-1 activation by the Gram-positive bacteria Staphylococcus aureus and 
Listeria monocytogeneses [31], [34]. Listeria monocytogeneses mediated caspase-1 
activation requires the bacterial toxin listeriolysin O (LLO). 
It is unlikely that these various stimuli can all activate NALP3 directly. More probably, 
a common intracellular “danger signal”, still unknown [35], is activated by these 
stimuli to trigger NALP3 activation. 
IPAF and the inf lammasome 
NALP3 is dispensable for caspase-1 activation in certain case, such as infection with 
Gram-negative bacteria Salmonella typhimurium and Francisella tularensis. 
IPAF is another 
NLR family 
member with a 
structure similar to 
 
NAD: NACHT-associated domain 
 Figure 6: NALP2/3 inflammasome. 
 
Figure 7: IPAF inflammasome. 
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that of NOD1. It’s a multidomain protein containing a CARD domain that, upon 
stimulation, can directly bind to caspase-1 (Fig. 7). 
IPAF is involved in caspase-1 activation following infection with Salmonella [28]. IPAF 
has also been recently identified to be required for flagellin to activate caspase-1. 
Salmonella strains deficient in flagellin were unable to activate caspase-1 [36], [37]. 
IPAF can directly bind to caspase-1 to activate it. Also, in mice, IPAF with NAIP 
recognizes intracellular flagellin from Legionella pneumophila, in order to induce 
caspase-1 activation [38], [39], [40]. 
It is still under debate whether ASC is required for activation of IPAF inflammasome 
[41]. [42], [43], [28], [36]. It seem that a partial requirement of ASC for IPAF-triggered 
activation of caspase-1 tend to be accepted. 
Other NLRs involved in activation of  caspase-1  
Other NLRs seems to be involved in activation of caspase-1 since the NLRs 
responsible for activating caspase-1 in response to F. tularensis has not yet been 
identified although NALP3 and IPAF have been excluded [31]. 
Finally, neuronal apoptosis inhibitory protein (NAIP)5 and NALP6 are involved in 
caspase-1 activation [38], [10]. NAIP is proposed to interact with IPAF indicating that 
it may be part of the same caspase-1 activating complex [38].  
NOD, NALP and IPAF inflammasomes are the cytoplasmic bacterial dectector of both 
pathogens and danger signal (Fig. 8). The activation and signaling of these 
inflammasomes are interconnected and lead to an inflammatory response by 
activating proinflammatory cytokines. 
Inflammasome assembly leads to the activation of inflammatory caspases. This 
results in the cleavage and activation of proinflammatory cytokines, mainly IL-1β and 
IL-18. 
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Inflammatory caspases 
Caspases: role in apoptosis,  inflammation and more 
Caspases (cysteinyl aspartate proteases) are a family of cysteine proteases. They 
are intracellular proteases that are common to multicellular organisms. Caspases 
fulfill roles in mammalian apoptosis or inflammation by proteolytic activation of 
cytokines. Caspases recognize a tetrapeptidic sequence and have a stringent 
specificity for cleaving the peptide bound C-terminal to aspartic acid residues. They 
use a cystein residue as the catalytic nucleophile. 
Currently, 14 caspases have been identified in mice and human and these represent 
at least 11 different activities. Whereas caspase 1-3, 6-9 and 14 are present in both 
human and mice, human caspase-4, -5 and -10 have no counterpart in mice. 
Conversely, mice caspase-11 and -12 have no counterpart in humans [44], [45]. 
A phylogenetically distinct class of caspases (caspase-1, -4, -5, -11 and -12) in 
vertebrates triggers the release of inflammatory mediators through the proteolytic 
from Akira et al. Cell (2006) 
Figure 8: Cytoplasmic bacterial detectors and their signaling. 
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processing of the precursors of the inflammatory cytokines IL-1β and IL-18 [26]. As 
their prime function is the regulation of inflammatory processes, they are called 
inflammatory caspases. Although caspases in the inflammatory family can trigger cell 
death in some cell types, a clear distinction was originally drawn between the 
apoptotic and inflammatory caspases based on their participation in separate 
signaling cascades and their substrate specificities. 
 
Caspases can be divided into 2 subgroups: the initiator and the executioner or 
effector. The subset of caspases that cleave selected substrates to produce the 
changes associated with apoptosis are known as effector caspases. In mammals, it 
is the caspase-3, -6 and -7. These executioner caspases are activated by initiator 
capases, which are caspase-8, -10, -2 and -9. Other initiator caspases are caspase-
1, -4, -5, -14. 
Inflammatory caspases 
Inflammatory caspases have 
been found only in vertebrates 
so far. In mammals, there are 
5 inflammatory caspases (-1, -
4, -5 in human and -11 and -12 
in mouse) that all have a 
CARD at their N-terminus, 
followed by the catalytic 
domain [26] (Fig. 9). Four 
genes in the human genome 
encode for decoy caspases: cop, inca1, inca2 and iceberg. They are devoided in the 
catalytic domain, only composing of the CARD domain (Fig. 9). 
 
 Caspase-1 and its substrate IL-1β 
Caspase-1 is the best-characterized inflammatory caspase. Caspase-1 was originally 
identified as a result of attempts to purify the enzyme responsible for the processing 
of pro-IL-1β [46]. IL-1β mRNA encodes for a 33KDa cytosolic pro-IL-1β protein that 
requires proteolytic cleavage for secretion and function as an active protein. 
from Martinon et al. Cell (2004) 
Figure 9: Human inflammatory caspase 
and decoy caspases. 
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Cleavage gives rise to a 17KDa C-terminal mature cytokine [47], [48]. IL-1β is a 
major mediator of inflammation and, in general, initiates and/or amplifies a wide 
variety of effects associated with innate immunity and host responses to microbial 
invasion and tissues injury [49]. The biological activity of IL-1β is directly associated 
with caspase-1 activation. 
Considering inflammasome-mediated caspase-1 activation and IL-1β production, in 
all situations studied to date, TLR priming (for example, LPS stimulation through 
TLR4) is absolutely required in addition to the inflammasome-activating stimulus (for 
example, bacterial RNA and Salmonella) [27], [31], [32], [33]. This requirement is for 
the induction of IL-1β but it also seems to be important for the expression and 
modification of other proteins that are required for inflammasome function. Thus, TLR 
and NLR pathways are clearly integrated for producing IL-1β, which initiates an 
inflammatory response. Thus, IL-1β plays a key role in signaling for host defense and 
inflammation during bacterial infection. 
In addition to the processing of IL-1β, caspase-1 can activate other proinflammatory 
cytokines, IL-18 [50] and IL-33 [51].  
Furthermore, caspase-1 is required for efficient expression of IL-1α, for unclear 
reasons [52, 53], but it’s cleaved by calcium-dependant calpain proteases [54]. 
 
 Mouse Caspase-11 and human caspase-4 and -5 
Mouse caspase-11 and -12 and human caspase-4 and -5, have no specific 
substrates identified up to now. Mice deficient in caspase-11 have a phenotype 
similar to caspase-1 deficient mice. They fail to produce mature IL-1β and are 
resistant to endotoxic shock induced by bacterial endotoxins [55]. It seems that the 
caspase-11 is an upstream activator of caspase-1 [55]. 
According to its sequence homology and its expression pattern, caspase-5 is 
proposed to be the homologue of mouse caspase-11 [56]. Caspase-1 and caspase-5 
are part of the NALP1 inflammasome. Thus, different inflammatory caspases may 
cooperate for full activity. Sequence comparison of the caspase domain and 
prodomain of the inflammatory caspases suggests that both caspase-4 and -5 
probably arose following the duplication of caspase-11 ancestor gene [26]. 
Very recently, a role for caspase-4 in endoplasmic reticulum stress induced apoptosis 
has been proposed [57], [58], that was challenged by other study [59]. 
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Caspase-12: a role in sepsis and endoplasmic stress? 
Conditions interfering with the function of endoplasmic reticulum are collectively 
called endoplasmic reticulum stress. Endoplasmic reticulum stress is induced by 
accumulation of unfolded protein aggregates or by excessive protein traffic usually 
caused by viral infection. The endoplasmic reticulum stress possesses its own 
signaling pathways that ultimately may result in cell death. Caspase-12 deficient mice 
suggest that this caspase is involved in endoplasmic reticulum stress induced 
apoptosis [60]. Also, caspase-12 is involved in the development of certain 
neurodegenerative disease such as Alzheimer or prion disease that present an 
endoplasmic reticulum stress [60], [61]. Eventhough, its role is still challenged [62], 
[63]. However, proteolysis of caspase-12 is a well-established hallmark of 
endoplasmic reticulum stress. 
In humans, a polymorphism in caspase-12 results in the production of either a 
truncated CARD-only protein [64] or a full-length caspase molecule, which appear to 
be enzymatically inactive [45]. Thus, the caspase-12 in human appears to function as 
a dominant-negative regulator of proinflammatory signaling pathways, including the 
IL-1 and NK-κB pathways. It is a decoy caspase for blocking caspase-1 activation 
[62]. 
Activation of inflammatory caspases 
All caspases are produced in cells as catalytically inactive zymogens (precursors), 
and generally undergo proteolytic processing during activation. Up regulated caspase 
activity would be lethal for a cell, that’s why, the cell stores the caspases as latent 
precursors.  
The N-terminal of the prodomain in procaspases contains a highly diverse structure 
required for caspase activation. They are all capable of auto-activating as well as 
activating other caspases, to produce a heterodimer with a small and a large subunit, 
and two heterodimers form an enzymatic active heterotetramer. For example, the 
45KDa precursor of caspase-1 is recruited upon specific stimulation into the 
inflammasome complex and can be cleaved to produce a dimer composed of a 
10KDa and a 20KDa chain. 
Active caspases are obligate dimers with two identical catalytic sites (Fig. 10). Unlike 
the zymogen form of effector caspases that exist as preformed dimers and that are 
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activated by 
specific proteolytic 
cleavage in the 
linker region 
between the large 
and the small 
subunit [65, 66], 
initiator caspases 
exist within the cell 
as inactive 
monomers (Fig. 
10). Their 
proteolytic 
processing after 
dimerization is not 
essential for 
activation [65, 66], 
[67]. The monomeric inactive precursors only require dimerization (or 
oligomerization) to assume an active conformation. Further processing of the initiator 
caspases plays a role in the stabilization of the active enzyme [65, 66], [68]. 
Dimerization of initiator caspases is triggered by specialized multimeric plateforms 
that allow recruitment of multiple caspase molecules into a complex. This brings 
initiator caspases into close proximity, provoking their activation. 
 
 
As apparent from the above review, most of the current research on innate immunity 
and in particular TLR-NLR-RLRs has been focused on the detection of foreign micro-
organism. The identified stimuli of these receptors are mostly constituents of the 
microorganism such as LPS, proteoglycan or specific nucleic acids. It is however not 
unlikely that these danger detecting devices are also involved in sensing the 
presence of virulence factor, such as for example toxins. To address this issue, we 
focused our attention of the largest class of toxins produced by bacteria, the pore-
forming toxin that composes 25% of all known protein toxins. 
 
Figure 10: A model of activation of Caspases. 
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AEROLYSIN AND RELATED AEROMONAS  
TOXINS 
As contributors to their virulence, many pathogenic bacteria produce protein toxins. 
The largest class of these is composed by the pore-forming toxins (PFTs), which 
make up some 25% of all toxins. Some bacteria produce PFTs directed towards 
other bacteria such as colicin producing E. coli. Most bacteria, however, produce 
PFTs directed towards eucaryotic host cells. These latter toxins share a similar mode 
of action despite their lack of sequence homology. The toxin is produced in a water-
soluble form that may or not require proteolytic processing. The toxin then diffuses 
towards the target cell with which it binds with high affinity via the interaction with a 
receptor, which can either be a protein, a lipid or a carbohydrate moiety. Cell surface 
concentration of the toxin promotes oligomerization into a ring-like structure that 
subsequently inserts into the membrane and forms a pore. Production of PFTs is 
common to Gram-positive and Gram-negative bacteria and is a phenomenon also 
found in parasites. 
 
One member of this large family of PFTs is aerolysin produced by Aeromonas 
species. Aeromonas species are Gram-negative bacteria found in fresh water 
environments throughout the world [69]. Members of the genus are pathogenic to 
many species including amphibians, fish, reptiles and humans and are major source 
of economical losses in aquaculture [70]. In humans, Aeromonas spp., including A. 
hydrophila, A. caviae, A. veronii biovar sobria, A. sobria, A. jandaei and A. veronii 
biovar veronii, have been involved in wound infections, sepsis, outbreaks of water- 
and food-borne gastroenteritis [71, 72] and is an emerging pathogen in immuno-
compromised hosts.  
Amongst the variety of potential virulence factors produced by Aeromonas spp., 
aerolysin has been considered the most important toxin as illustrated by the facts that 
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aerolysin is lethal to mice [73], that immunization against the toxin leads to the 
protection towards the bacterium and that aerolysin deficient strains are significantly 
less toxic than the parental strain, in a mouse model [74].  
Production ,  purification and primary 
structure 
Production of high amounts of aerolysin was made possible by expressing the gene 
in low protease producing A. salmonicida strains allowing purification, using a two 
step chromatography, of the precursor protein, proaerolysin, from the bacterial 
supernatant [73, 75]. Proaerolysin can also be produced in E. coli using vectors that 
allow expression of the protein in the periplasm of the bacterium–to allow disulfide 
bond formation (see below) – with a C-terminal histidine tag and purification with 
nickel columns [76].  
Structure of proaerolysin 
The toxin is synthesized as a pre-proaerolysin, with a N-terminal signal sequence 
that directs it to translocation across the inner bacterial membrane and a C-terminal 
precursor peptide. The signal sequence is removed upon translocation and the 
precursor, proaerolysin, is then secreted to the extracellular medium. Proaerolysin is 
a 470 amino acid long chain, with a molecular mass of approx. 52KDa and no 
hydrophobic stretches in contrast to most membrane spanning proteins. When the 
sequence was obtained, this observation lead to the prediction that aerolysin would 
not cross the membrane as hydrophobic α-helices but rather as a β-barrel, as do 
bacterial outer-membrane porins [77]. 
This prediction was supported by the X-ray structure of proaerolysin [78] (Fig. 11), 
which revealed a protein rich in β-structure with little α-helical structure in agreement 
with circular dichroism data (42% β and 21% α structure) [79]. The protein was found 
to be an L-shaped molecule, divided into a small N-terminal lobe (domain 1) and a 
large lobe, composed of 3 additional domains. Two disulfide bonds (C19-C75 in 
domain 1 and C159-C164 in domain 2) were predicted by the structure, and 
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confirmed experimentally, that stabilize the toxin and protect the 154-167 loop from 
proteolysis [80]. 
Proaerolysin crystallized as a head to tail dimer, not surprisingly since dimers can be 
found in solution [81, 82] at toxin concentrations above 0.1 mg/ml [83]. Dimerization 
involves a domain swapping interaction between domain 1 of one monomer and the 
large lobe of the adjacent monomer. It is not yet clear why dimerization occurs but 
presumably it confers stability to the protein or reduces its sensitivity to proteases. 
Another possibility is that dimerization is required for the secretion of proaerolysin by 
the bacterium (see below).  
Domain 1, the only domain that is continuous in sequence (residues 1-82) plays an 
important role in receptor binding (through residues Trp-45, Ile-47, Met-57 and Lys-
66, Fig. 12) [84] and is involved in dimerization. This domain shows a strong 
structural homology with a fold found in S2 and S3 subunits of pertussis toxin of 
Bordetella pertussis [85] and similar folds are found in C-type lectins suggesting a 
role in carbohydrate binding (see below). Domain 2 (residues 83-178, 311-398) also 
 
Figure 11: Structre of aerolysin monomer. 
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plays an important role in receptor binding (through residues Tyr-162, Trp-324, His-
332, see below) [84] and additionally is important in the initiation of oligomerization 
[86]. Interestingly, domain 2 contains most of the α-helical structure of the protein. 
Domain 3 (residues 179-195, 224-274, 299-310 and 399-409) is thought to play an 
important role in monomer-monomer interactions within the oligomer [80]. A particular 
loop alternating charged and none charged amino acids (residues 239-264), has 
recently been shown to be crucial in membrane insertion and chanel formation [87] 
as discussed below. Domain 4 (residues 196-233, 275-298 and 410-470) contains 
the peptide that is proteolytically removed upon conversion of proaerolysin into 
mature aerolysin and was thought to be responsible for channel formation [78], a 
view that has been recently challenged as discussed below.  
Interestingly, the structure of Clostridium perfringens epsilon toxin was recently 
solved [88]. Although this toxin shares only 13.9% identity with aerolysin, it has 
essentially the same mode of action (proteolytic activation of a precursor, receptor 
binding and heptamerization, [89]) and above all a structure remarkably similar to that 
of the large aerolysin lobe [88] (Fig. 12) except for the region corresponding to 
domain 2 of aerolysin. This difference suggest that epsilon toxin might bind to 
different receptors than aerolysin, a notion that is further supported by the potency of 
this toxin which is effective at 100 fold lower concentration and shows a strong cell 
type specificity. 
Receptor binding 
Once in the extracellular milieu, proaerolysin diffuses towards its target cells. Both 
proaerolysin and mature aerolysin (see below) have the ability to bind specifically to 
cells. Although the toxin may exist as a dimer, surface binding occurs in the 
monomeric state [83]. Binding to mammalian cells was found to be specific and 
saturable [90] indicating the existence of a surface receptor. Moreover no species or 
cell type specificity was found suggesting that the receptor was ubiquitous. In the late 
90’s, proaerolysin was indeed found to bind to glycosylphosphaditylinositol (GPI) 
anchored proteins, which are ubiquitous [90-93]. Interestingly the main binding 
determinant turned out to be the glycan core of the anchor. This post-translational 
modification is present through out evolution from protozoa to mammals [94, 95]. GPI 
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anchored proteins (GPI-AP) have no transmembrane domains, and thus no cytosolic 
domain. The protein is attached to the cell surface via the GPI anchor, which is 
composed of a specific phospholipid, phosphatidylinositol (PI), on which are 
sequentially linked a glucosamine, 3 mannose residues and an ethanolamine 
phosphate which is linked by an amide bond to the C-terminus of the protein (Fig. 
12). The inositol ring of the GPI is initially acylated during biosynthesis of the GPI 
anchor and subsequently deacylated except in certain cell types such as human 
erythrocytes [94, 95]. The conserved GPI glycan core can be additionally modified in 
a great variety of manners, depending on the species, on any of the different sugars 
[94, 95]. Modification of the second mannose by addition of a beta-N-
acetylglucosaminyl phosphate diester residue was found to be crucial for aerolysin 
binding [96] (Fig. 12). Acquisition of a presynthesized GPI anchor by a newly 
synthesized protein occurs after the removal, in the endoplasmic reticulum lumen, of 
a C-terminal GPI anchoring signal sequence. The lipid-anchored protein is 
subsequently transported to the plasma membrane. 
 
The GPI glycan core 
shows a GlcNac (N-
acetylglucosamine) 
modification on the 
second mannose that 
is important for 
receptor binding. 
Asn : Asparagin, 
Etn : Ethanolamine, 
In : inositol, P : 
phosphate group, 
Glc : Glucose, Man : 
Mannose. 
Figure 12: Schematic representation of aerolysin bound to its 
glycosylated GPI-anchored receptor. 
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Several lines of evidence support that GPI-anchored proteins are the receptor of 
aerolysin. Treatment of cells with a phosphatidyl inositol-specific phospholipase C 
(PI-PLC), which removes the GPI-AP from the surface of the cell, leads to a decrease 
in sensitivity to aerolysin, except for human erythrocytes due to acylation of the 
inositol ring. Also GPI deficient cells have a 3 fold reduced sensitivity to aerolysin [93, 
Gordon, 1999 #2171]. And finally, screening for aerolysin resistant Chinese hamster 
ovary (CHO) mutants led mostly to cells defective in GPI biosynthesis [97, 98].  
Since the glycan core is the main binding determinant and since it is common to all 
GPI-anchored proteins, aerolysin is in principle able to bind to all GPI-anchored 
proteins. Indeed, aerolysin was found to bind to a great variety of GPI-anchored 
proteins, that have no sequence homology, such as: Thy-1, a major surface 
glycoprotein of T-lymphocytes and mammalian neurons [93], contactin, a brain cell 
adhesion molecule [92], CD14, a monocyte differentiation factor also involved in 
lipopolysaccharide signaling, semaphorin K1, a brain GPI-anchored protein, 
carboxypeptidase M (unpublished) and the GPI anchored form of adhesion molecule 
N-CAM [99]. Three mammalian exceptions have however been found the 
complement inhibitory protein CD59 [100] and the prion protein (unpublished) as well 
as Leshmania gp63 [100]. This parasite protein however was able to bind aerolysin 
when expressed in mammalian cells [92] suggesting that modifications of the glycan 
core in the parasite hinder aerolysin binding. 
Although the identity of the protein attached to the GPI anchor does not influence 
binding, the presence of the protein was found to be necessary since aerolysin does 
not bind to protein free GPIs [100]. This is because the protein harbors a second 
binding site for the toxin as recently found in a screen for low aerolysin binding CHO 
cells [98] (Fig. 12). Interestingly, as for the first receptor-binding site, the toxin does 
not recognize the polypeptide but a second post-translational modification: the 
presence of N-linked sugars. Endoplasmic reticulum N-linked glycosylation is 
however not sufficient for aerolysin binding, the N-glycan needs to be properly 
trimmed. More specifically, a-mannosidase II in the Golgi must remove mannoses 
from the complex glycan initially added to asparagine residues in the endoplasmic 
reticulum [98]. Addition of terminal galactose and syalic acid was not required 
indicating that the minimum N-glycan structure for aerolysin binding is Gn-M3-Gn2-N 
(Gn, N-acetylglucosamine; M, mannose; N, asparagine) (inset in Fig. 12). Since all 
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known GPI-anchored proteins are glycosylated and often hyperglycosylated, this 
second binding site does not reduce the number of potential receptors.  
To the two binding sites on the aerolysin receptors correspond two binding sites on 
the toxin, one in domain 1 [101] and the second in long lobe of the protein [102] (Fig. 
12). This notion was initially proposed by Buckley and colleagues based on the 
observations that a hybrid toxin composed of domain 1 (Fig. 12) of aerolysin followed 
by the α-toxin of Clostridium septicum (Fig. 11, which is homologous to aerolysin but 
lacks domain 1) had a higher receptor binding affinity (approx. 50 times) than α-toxin 
alone [101], which also binds GPI anchored proteins [103]. More specifically, domain 
1 is involved in binding to the complex N-glycans [98]. Interestingly, recombinant 
domain 1 appeared to bind only to N-glycans that are present on GPI-anchored 
proteins, suggesting that it in fact recognizes a site to which both the N-glycan and 
the GPI-glycan core contribute. Mutation of residues Trp-45, Ile-47, Met-57, Tyr-61 
and Lys-66 lead to reduced receptor binding as measured by plasmon resonance 
using immobilized Thy-1 [84]. Binding to the GPI-anchor occurs via domain 2 
involving in particular Tyr-162, Trp-324 and His-332, which when mutated led to a 
decrease in Thy-1 binding affinity [84]. The combination of these two binding sites 
leads to the high affinity interactions of aerolysin with its receptors. The apparent Kd 
for binding of proaerolysin to baby hamster kidney (BHK) cells was estimated to be 
around 20nM [90] and similar value was found when measuring binding of 
proaerolysin to purified Thy-1 using plasmon resonance (66nM) [84]. Strikingly, many 
of the residues identified as being important for binding to either of the two 
carbohydrate sites are aromatic residues. Similar observations have been made for 
other carbohydrate-binding proteins in which aromatic residues have been shown to 
stack against the pyranose rings of sugars [104].  
It is still not fully understood how aerolysin binds to its receptor. Indeed it is not clear 
how domain 2, a rather large domain, can interact with a small glycan core, which is 
sandwiched between the polypeptide of the GPI-anchored protein and the membrane 
(Fig. 12). A second puzzle is the binding to N-linked sugars. How can aerolysin bind 
to almost any GPI-anchored protein despite the fact that these have N-linked sugars 
at different positions on their tertiary fold? Finally, even more mysterious is how 
aerolysin reaches its high-affinity binding site on the glycan core of the GPI-anchor. 
Indeed, this part of the receptor is very little exposed at the cell surface, especially in 
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intestinal cells. In order to cross the thick layer of glycocalyx covering epithelial cells, 
aeolysin may initially binds to surface oligosaccharides with low affinity, possibly 
through its lectin-like domain 1 or tryptophan rich regions of the molecule (18 in total), 
before being progressively shuttled to the membrane vicinity where it would bind to 
the glycan core of the GPI anchor [84]. This model of relay of low and high affinity 
binding site remains to be proven but is supported by the finding that polarized 
epithelial cells are always more sensitive to aerolysin from their apical side – more 
abundant in oligosaccharides – than from their basolateral side, irrespective of the 
localization of their GPI-anchored proteins [105]. 
From the precursor to the active toxin 
Conversion of proaerolysin to aerolysin requires proteolytic cleavage of a C-terminal 
peptide (Fig. 11), a step that can occur prior or subsequent to receptor binding. 
Cleavage can be achieved by a variety of enzymes either produced by the bacterium 
[106], or found in the digestive tract – such as trypsin [106] – or present at the 
surface of the cell – such as members of the furin family [107]. Three cleavage sites 
have been identified: Lys-427 by trypsin, Arg-429 by chymotrypsin [79] and Arg-432 
by furin [107] suggesting that the loop containing these residues (which was not seen 
in the crystal structure) is very sensitive to proteases.  
Proteolysis at the C-terminus – in domain 4 – leads to conformational changes that 
spread through out the entire structure all the way to domain 1 [108]. The exact 
changes have not been identified but a 10% increase in β-sheet structure at the 
detriment of random structure was measured by Fourier Transformed Infra Red 
spectroscopy (FTIR) with no major change in tertiary structure [108].  
Heptamer formation 
Once processed into aerolysin and bound to the receptor, the toxin undergoes 
oligomerization into a ring like structure composed of seven monomers (Fig. 13) as 
observed both by electron microscopy [109] and mass spectrometry [110]. While 
oligomerization can occur in solution, it is far more efficient at the surface of cells. 
This is to a large extend due to the increase in concentration that accompanies the 
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decrease in dimensionality when going from a three to a two dimensional space 
(estimated to be a 3000 to 10’000 fold increase). An additional concentration factor is 
provided by the association of the GPI-anchored receptors with special plasma 
membrane domains, or lipid rafts thus further promoting oligomerization [111] (Fig. 
13).  
The mechanism by which the heptamer assembles, i.e. does it assembles through 
gradual association of monomers, or do dimers and trimers form and then associate, 
has not been characterized. What is known is that oligomerization involves no 
change in secondary structure, as measured by circular dichroïsm (CD) [112], but the 
rearrangement of the tertiary organization as observed both by CD and FTIR [108]. 
This rearrangement leads to the formation of an extraordinarily stable structure, more 
so than heptamers of other toxins such as staphylococcal a-toxin. The incubation of 
the aerolysin heptamer in 8M urea for 24 hours does not affect its tertiary structure 
[80]. Heptameric assembly is also maintained in guanidium hydrochloride (6M), but 
this stronger chaotropic agent does however lead to loss of tertiary packing. Finally 
the heptamer is resistant to boiling in SDS [80]. 
In order to identify the regions involved in the tight maintenance of the complex, 
limited proteolysis studies were performed using the enzyme boilysin, an engineered 
enzyme, which retains its activity at high temperatures and even in the presence of 
SDS [113]. Boilysin treatment led to truncated but still oligomeric aerolysin 
complexes, the composition of which was identified by N-terminal sequencing and 
MALDI-TOF analysis [80]. Two fragments, corresponding to amino acids 180-307 
and 401-427, were identified showing that the domains 3 and 4 are crucial for 
maintaining the heptamers assembled while domains 1 and 2 are not required [80]. 
Figure 13: Mode of action of aerolysin. 
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Although domain 2 is not responsible for the extreme stability of the heptamer, it is 
involved in initiating the oligomerization process. Mutation of His-132 in domain 2 
completely abolishes in vitro heptamerization [114] and channel formation in planar 
lipid bilayers [115]. It was shown that protonation of histidine at position 132 is 
necessary for oligomerization [86]. This histidine has a very unusual environment that 
severely modifies its pKa allowing histidine protonation at physiological pH. Mutation 
of trypthophans at positions 371 and 373, also in domain 2, had the opposite effect 
since oligomerization was accelerated possibly by a partially destabilizing effect that 
favor the rearrangements leading to heptamerization [112]. 
Many PFTs, including staphylococcal a-toxin and cholesterol dependent toxins 
(CDT), first oligomerize into a pre-pore state and then undergoes a second concerted 
conformational change that leads to channel formation. In the case of aerolysin, there 
is no evidence for a pre-pore state and oligomerization appears to be systematically 
accompanied by the appearance of hydrophobic patches as witnessed by measuring 
binding of fluorescent hydrophobic dyes [112]. A very interesting aerolysin point 
mutation, Y221G, has however been identified that leads to a non-hydrophobic 
heptamer [76]. This mutant can still bind to GPI-anchored proteins and heptamerize 
but these heptamers cannot insert into membranes [76, 116].  
The aerolysin heptamer has a mushroom shaped structure (Fig. 14) in which 
domains 1 and 2 would form the cap, domain 3 the mouth of the channel and domain 
4 the transmembrane part.  
Figure 14: Space-filled model of the aerolysin Y221G 
heptamer. 
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Membrane insertion and channel 
properties 
Since aerolysin does not appear to transit through a pre-pore state, heptamerization 
is directly followed by membrane insertion. As for other β-sheet containing PFTs, 
channel formation is thought to occur by the formation and spontaneous membrane 
insertion of a β–barrel. Little is known about this last step, both in terms of the 
interaction with lipids and the structure of the transmembrane region. It has been 
suggested that the junction between lipid rafts and the fluid phase region is a site of 
unfavorable energetic effects and these unstable boundaries might provide a 
favorable insertion site [117]. Also, the insertion of aerolysin heptamers in artificial 
liposomes is enhanced by the presence of lipids favoring lamellar-to-inverted 
hexagonal phase transition [118]. These authors indeed showed that the rate of dye 
leakage from unilamellar egg-phosphatidylcholine vesicles is enhanced by the 
presence of phosphatidylethanolamine, diacylglycerol or cholesterol. On the other 
hand lipids that stabilize the lamellar phase such as sphingomyelin and saturated 
phosphatidylcholines reduced the rate of channel insertion. 
It is at present not clear which part of aerolysin actually forms the transmembrane 
region. The low and medium resolution models [76, 78] of the heptamer propose that 
domain 4 crosses the membrane. This model is however challenged by experiments 
that indicate that a loop in domain 3 (Fig. 12) is necessary for channel formation [87]. 
This loop, corresponding to residues 239 to 264, has previously been implicated in 
oligomerization since immobilization of this loop, by an engineered disulfide bond that 
links it to the protein core, inhibited heptamerization [119]. More recently we have 
found that restraining the flexibility of the loop, by disulfide bond engineering within 
the loop, does not prevent heptamerization but blocks channel formation [87]. Indeed, 
the loop can cross the membrane and form the transmembrane channel. Moreover 
this specific loop would be involved in anchoring tightly the channel to the membrane 
in a rivet model [87] Finally, the corresponding loop in C. Septicum α-toxin was also 
found to interact with the membrane [120].  
Electrophysiological measurements in planar lipid bilayers showed that aerolysin 
makes well defined, slightly anion selective channels with a single-channel 
conductance of 420pS [121, 122]. The channels remain opened in the range of -70 to 
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+70 mV and undergo voltage-dependent closing outside of this range. From the 
analysis of 2D crystals of the aerolysin heptamers the measured inner-diameter of 
the channel was estimated at 17 Å [76, 78] but somewhat greater diameters were 
reported from small-molecule release experiments (30 Å) [123] and optical single 
channel analysis (40 Å), [124]. In vivo data suggests that the channels formed in 
living cells are somewhat smaller as the heptamer seems to discriminate between 
ethidium monomer and ethidium dimer [125] and does not allow the passage of entire 
molecules of trypan blue (960Da) into cells [90]. 
Cellular consequences of aerolysin 
Upon channel formation in the plasma membrane of mammalian cells, aerolysin 
leads to the permeabilisation to small ions but not proteins [90]. As the pore allows 
ions to go through, this leads to a dissipation of the Na+ and K+ gradients and the loss 
of membrane potential [90, 126]. Importantly, aerolysin channels also allow the entry 
of extracellular calcium [125].  
In cells that are unable to repair or counteract membrane damage, this breach in 
plasma membrane permeability leads to osmotic lysis. However, except at late 
stages of Aeromonas infection when a bacteremia is reached, the toxin is unlikely to 
encounter erythrocytes. In nucleated cells, the consequences of membrane damage 
by aerolysin are however far more complex and are both concentration and cell type 
dependent. We will briefly describe some of the observed effects. The link between 
these various observations remains unclear and obtaining the full picture will require 
intensive further studies. The massive efflux of potassium and the entry of calcium 
are however two events that on their own are likely to cause a multitude of effects. 
Morphological changes 
At concentrations of 1nM and below, intestinal and other epithelial cells undergo 
cytoplasmic vacuolation These vacuoles were found to originate from the 
endoplasmic reticulum, leaving the endocytic compartments and Golgi complex 
morphologically unchanged [90, 107]. This process was inhibited when extracellular 
calcium was chelated with EGTA (unpublished) but was not solely dependent on 
calcium entry since calcium ionophores did not lead to ER vacuolation [90]. 
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Endoplasmic reticulum vacuolation was dependent on the dynamic properties of the 
compartment since vacuolation was inhibited by ATP depletion or depolymerisation 
of the microtubules network [90]. Induction of neutral pH cytoplasmic vacuoles was 
also observed for other pore-forming toxins such as Staphylococcal a-toxin [90], 
Serratia marcescens hemolysin [127] and Vibrio cholera hemolysin [128, 129], 
although in the two later cases the ER was not formally identified. ER vacuolation 
was however not observed for Streptolysin O, possibly because it forms larger pores 
[130]. Note that these PFT induced vacuoles differ from those induced by the 
Helicobacter pylori vacuolating toxin VacA, which leads to acidic vacuoles that 
originate from late endocytic compartments [131].  
In addition to the appearance of cytoplasmic vacuoles, intestinal and epithelial cells 
often also undergo plasma membrane blebbing when exposed to aerolysin [90, 107, 
132]. 
Changes in gene expression and production in 
proinflamatory molecules 
Chopra and colleagues have extensively analyzed the changes in gene expression 
upon exposure to aerolysin both of RAW macrophages and of primary macrophages 
[73, 133, 134]. These studies have led to the identification of some 200 up and 200 
down regulated genes between 0 and 12 h of toxin treatment. Further studies will be 
required to understand how these genes fall into pathways and what their relevance 
is. Immediately apparent however, and perhaps not surprisingly, aerolysin was found 
to trigger the production of a variety of proinflammatory molecules, in particular 
Tumor necrosis factor α (TNFα), interleukin 1ß (IL-1β), interleukin 6 and 
protasglandin E2 [73, 133-135]. Aerolysin was also found to induce the expression of 
nitric oxyde synthase (iNOS), possibly via upregulation of TNF-a and IL-1 in the host 
cell [73]. Nitric oxyde (NO) production by iNOS is an essential element of 
antimicrobial immunity and host-induced tissue damage. 
Induction of apoptosis 
That aerolysin triggers apoptosis was first observed on T lymphocytes, as witnessed 
by DNA laddering, an event that could be overcome by the overexpression of bcl2 
[116]. Since aerolysin was also shown to trigger apoptosis in murine macrophages 
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[133] and intestinal cells [132] but not on fibroblast like cells [90]. Note however that 
different assays were used by different laboratories to monitor apoptosis including 
DNA condensation and genomic DNA laddering, annexin V binding.  
The pathway(s) by which aerolysin triggers apoptosis has not been elucidated. Entry 
of calcium through the aerolysin channel has been proposed to be the cause [116]. A 
recent study however suggests that apoptosis could be a secondary effect due to the 
toxin-induced production of TNFα [132]. Galindo et al. indeed observed that 
apoptosis, and the concurrent cleavage of caspase 3, was drastically reduced in 
aerolysin treated macrophage lacking the two TNF receptors TNFR-1 and TNFR-2 
[132]. 
Activation of signaling pathways 
The first evidence that aerolysin was able to trigger signaling cascades came from 
the observation that channel formation led to the activation of Pertussis sensitive G 
proteins that subsequently led to the production of inositol (1,4,5)-triphosphate (IP3) 
and the release of calcium from the endoplasmic reticulum via IP3 dependent 
channels [125]. It was indeed apparent from this study that increases in cytoplasmic 
calcium were not only due to entry of the ion through the toxin channel at the plasma 
membrane but also that the toxin triggered release from intracellular stores. 
Intracellular calcium release was clearly dependent upon pore formation, and not 
binding or clustering of GPI-anchored proteins, since channel impaired mutants (such 
as Y221G or G202C-I445C) had no effect. How aerolysin is able to trigger activation 
of G proteins remains mysterious but could involve stretch or stress activated 
receptors. Another possibility is that the aerolysin channels affect the integrity of 
rafts, which have been implicated in modulating and integrating signaling events at 
the plasma membrane [136]. In agreement with the activation of G-proteins, aerolysin 
was found to stimulate chemotaxis [125, 137]. 
In addition to G proteins, aerolysin triggers the activation of multiple signaling 
cascades. Activation of p38, ERK1/2 and JNK kinases as well as some of their 
upstream effectors and downstream targets has been observed [132] indicating that 
aerolysin activates three of the major MAPK signaling routes present in cells involved 
in cell proliferation, differentiation, apoptosis and inflammation.  
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Evidence that cells mount a defense against aerolysin 
The fact that perforation of the plasma membrane triggers a great variety of effects in 
the host cell, leading to the up and down regulation of genes, is not so surprising but 
thorough analysis of the mechanisms involved is now required. 
Most astonishing is the recent finding that cells, and organisms, actually mount a 
defense against pore-forming toxins. The observation was originally made by gene 
expression analysis of Caenorhabditis elegans challenged with an insecticidal pore-
forming toxin [138]. As for aerolysin treated macrophages, pore-forming toxins 
treated C. elegans led to the up and down regulation of a variety of genes, amongst 
which the C. elegans homologue of p38 MAPK. Aorian and colleagues subsequently 
showed that worms harboring a mutation in this gene were hypersensitive to the toxin 
[138]. These studies were extended to mammalian cells and aerolysin and indicated 
that cells treated with a p38 MAPK inhibitor died more rapidly than control cells [138]. 
This is the first time that a survival pathway is observed as being activated and 
functional against PFTs. The survival strategy of cells, linked to the innate immune 
system, is likely to include other pathways, which is the subject of my thesis. We 
found that one of the survival strategies the cell uses is to regulate the key regulators 
for cholesterogenesis and lipogenesis, SREBPs 
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STEROL REGULATORY ELEMENT BINDING 
PROTEINS 
In animals, lipids have multiple roles. It’s a vital component of cell membranes 
without which cells cannot function, but it’s also the precursor to all steroids 
hormones, vitamins, bile acids, eicosanoids and oxysterols, which by themselves are 
important regulatory molecules in many metabolic pathways. Cholesterol and fatty 
acids as building blocks of cell membranes are synthesized via regulated pathways. 
All cells must control tightly these pathways in order to maintain levels within 
physiological boundaries. Excessive amounts of cholesterol in cells can destroy 
membrane function, precipitate as crystals which will kill the cell or result in 
artherosclerotic damage if spread to blood. 
The diet and endogenous synthetic pathways supply our requirement for lipids. The 
synthesis of fatty acids and cholesterol, which in turn give rise to multiple lipid 
compounds, can occur in any cell but these pathways are particularly important in 
liver and adipose tissues, organs specialized in export or storage of lipids. Both 
cholesterol and fatty acid biosynthetic processes are controlled by a common family 
of transcription factors designed sterol regulatory element binding proteins 
(SREBPs). SREBPs transcriptionnally activate a cascade of enzymes required for 
endogenous cholesterol, fatty acid, triglyceride and phospholipids synthesis. Thus 
SREBPs are considered as the master regulators of cholesterogenesis and 
lipogenesis. 
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Structure of the membrane bound 
transcription factor 
SREBPs belong to the large family of basic helix-loop-helix-leucine zipper (bHLH-Zip) 
transcription factors. Three members of SREBPs family have been identified, 
SREBP-1a, SREBP-1c, SREBP-2 [139, 140]. They are synthesized as inactive 
precursors that have a molecular size of about 125KDa and consist of about 1150 
amino acids. Interestingly, those precursors are transmembrane proteins of the 
endoplasmic reticulum [141] (Fig. 15). 
Isoform -1a and -1c are produced from a single gene (SREBF-1) on human 
chromosome 17p11.2 by use of alternate promoters and splicing, resulting in different 
forms of exon-1 [140], [142], [143] (Fig. 15). The use of alternative transcription start 
sites gives rise to isoforms differing in their first exon (exon 1a and exon 1c) (Fig. 15). 
The other exons are common to both isoforms. 
SREBP-2 is encoded by a separate gene (SREBF-2) on human chromosome 22q13 
[140], [142], [143], [139], [144] (Fig. 15). SREBP2 shares 47% of sequence identity 
with SREBP-1. 
 
All SREBP precursors are double spanning transmembrane proteins with N and C 
termini into the cytoplasm. They are all organized as follows. 
from Eberlé et al. Biochime (2004) 
Figure 15: SREBPs genes and structure. 
TA: transactivation domain. 
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 First, an NH2-terminal domain of about 480 amino acids contains the 
transactivation domain and a bHLH-Zip region. This acidic region is rich in serine and 
proline in SREBP1 and rich in serine, proline and Glycine in SREBP2. Both the 
transactivation domain and the bHLH-Zip region mediate the full transcriptional 
activity of SREBPs. 
The very NH2-terminal acidic domain has to bind transcription coactivators to achieve 
full activation, [145], [146] (see above). This acidic domain is indeed essential for 
function, since, when removed, the bHLH-Zip domain is no more transcriptionally 
active, even if still binding to DNA [147], [148]. It can thus act as an inhibitor [147]. 
Adjacent to this acid DNA-binding domain is a variable area rich in serine, proline, 
glutamine and glycine. Next follows the bHLH-Zip domain, whose basic region 
mediates DNA binding. The rest of this region gives the ability to dimerize. SREBPs 
can either homodimerize or heterodimerize with another SREBP molecule but not 
with another bHLH-Zip transcription factor [149], [150], [151]. The rest of the SREBP 
molecule has no analogy with other bHLH-Zip transcription factor. 
The following central portion of SREBP is the membrane-anchoring region, 
which is about 90 amino acids long. It consists of 2 hydrophobic, membrane-
spanning segments separated by a hydrophilic loop, of about 30 amino acids, which 
extends into the lumen of the endoplasmic reticulum.  
 The COOH terminal segment of about 590 amino acids again extends into the 
cytosol and serves as the regulatory domain for transformation into the mature and 
transcriptionally active form of SREBPs. Neither the membrane spanning, nor the 
regulatory regions, is found in other bHLH-Zip transcription factors [152].  
SREBPs activation 
Upon activation, the endoplasmic reticulum-anchored SREBP precursor undergoes a 
sequential two-step cleavage process to release the NH2-terminal active domain, 
designated the nuclear form of SREBP (nSREBP). After nucleus translocation, 
nSREBP promotes the expression of many genes involved in cholesterogenesis and 
lipidogenesis. 
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SREBPs activation by proteolytic cleavage 
Following SREBP mRNA translation, 
SREBP precursors are retained in the 
endoplasmic reticulum membranes 
through a tight association with SREBP 
cleavage activating protein (SCAP). 
SCAP is a 1276 amino acid polytopic 
membrane protein that is required for 
the movement of SREBP from the 
endoplasmic reticulum to the Golgi 
apparatus. Under the appropriate 
conditions, SCAP escorts the SREBP 
precursors to the Golgi where two 
functionally distinct proteases, site 1 
protease (S1P, a membrane-anchored 
serine protease of the subtilisin family) 
and site 2 protease (S2P, a 
transmembrane zinc metalloprotease), 
sequentially cleave the precursor 
protein releasing the nSREBPs in the 
cytoplasm [153], [154] (Fig. 16). First, 
S1P cleaves within the hydrophilic 
luminal loop of the SREBP precursors, 
between the leucine and the serine in 
the sequence RSVLS [155], [156] (Fig. 
16). This first cleavage generates an intermediate NH2-terminal fragment of the 
approximate size of the nSREBP [154] (Fig. 16). This fragment remains bound to the 
membrane through a single membrane-spanning helix (Fig. 16). S2P then cuts the 
protein within the first transmembrane fragment [155] thus releasing the active NH2-
terminal fragment, which can then enter the nucleus and regulates the transcription of 
a variety of sterol-responsive genes [157], [158] (Fig. 16). Cleavage at site 2 is 
strongly dependent on the tetrapeptide DRSR that precedes the first transmembrane 
domain (Fig. 16). The cleavage occurs into the hydrophobic segment, 3 residues to 
from brown et al. cell (1997) 
Figure 16: The two step cleavage 
of SREBP activation. 
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the COOH terminal side of the DRSR sequence, between a leucine and a cystein 
amino acid. The first S1P cleavage is absolutely required for the second S2P 
cleavage to occur and is dependant on the size of the luminal domain [159]. The S1P 
and S2P proteases are not specific to SREBPs and are involved in other 
transmembrane protein cleavages such as the activating transcription factor 6 (ATF6) 
or CREB4 [160]. This regulated intramembrane proteolysis mechanism also occurs 
for other proteins such as amyloid β peptide, Notch [161], [162]. 
Role of SCAP in SREBP trafficking 
The NH2-terminal domain of SCAP consists of 730 amino acids organized into eight 
membrane- spanning segments. Within this segment, there are three N-linked 
oligosaccharide chains attached to the lumenal loops. The COOH-terminal 
cytoplasmic domain consists of 546 amino acids and includes five copies of a WD 
repeat (tryptophan–aspartate repeat), which represents a protein-protein interaction 
motif required for the binding of SCAP to the COOH-terminal domain of SREBP. 
SCAP/SREBP trafficking is regulated by cholesterol. When endoplasmic reticulum 
membranes are 
cholesterol poor, the 
SCAP/SREBP traffics 
from the endoplasmic 
reticulum to the Golgi 
where it is sequentially 
cleaved by S1P and 
S2P, releasing an active 
fragment to the nucleus 
to upregulate genes 
involved in sterol and 
fatty acid synthesis (Fig. 
17). When endoplasmic 
reticulum membranes 
are cholesterol replete, 
the SCAP/SREBP 
complex fails to exit the 
From Horton et al. J. clin. Invest. (2002) 
Figure 17: Sterol mediated proteolytic release 
of SREBPs from endoplasmic reticulum 
membranes. 
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endoplasmic reticulum and is not accessible to Golgi-resident proteases resulting in 
negative regulation of sterol synthesis (Fig. 17). This feedback mechanism allows 
maintenance of a critical concentration of membrane cholesterol [152] [157], [163]. 
The mechanism by which sterols block SCAP/SREBP exit from the endoplasmic 
reticulum occur via interaction with a “sterol-sensing domain” within the polytopic 
membrane attachment domain of SCAP [164], [165], [166]. This sterol-sensing 
domain of SCAP is an pentahelical region located in a 767 amino acid octahelical 
membrane region. Cholesterol can bind with high affinity and specificity to this 
octahelical region [164] (Fig. 18).  
The pentahelical sterol-sensing 
domain is also found in 6 other 
polytopic membrane proteins. These 
include (1) the cholesterol 
biosynthetic enzyme 3-hydroxy-3-
methylglutaryl coenzyme A reductase 
(HMG CoA reductase), whose 
ubiquitination and degradation is 
accelerated by sterols; (2) the lipid 
transport protein known as Neimann 
Pick C1 (NPC1) that is defective in a 
human cholesterol-storage disease; 
(3) the developmental protein 
Patched whose ligand, Hedgehog, is 
the only known protein to which 
cholesterol is covalently attached; (4) 
the membrane protein Dispatched 
that facilitates the release of 
Hedgehog from Hedgehog-producing cells; and (5) the penultimate enzyme in the 
cholesterol biosynthetic pathway, 7-dehydrocholesterol reductase, whose genetic 
absence causes developmental abnormalities in patients with the Smith-Lemli-Opitz 
syndrome [164], [167], [168], [169] (Fig. 18). The most recent sterol-sensing protein 
to be described is the transport protein, NPC1L1 that facilitates the intestinal 
absorption of dietary cholesterol in humans and rodents [170]. Cholesterol binds to 
From Kuwabara et al., Trends in genetics (2002) 
Figure 18: Sterol-sensing domain 
containing protein. 
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sterol-sensing domain of SCAP and induce a conformational change in SCAP. This 
conclusion was reached on the basis of protease protection studies performed with 
intact endoplasmic membrane vesicles [171], [172].  
Role of INSIG in SREBP processing 
To ensure the retention of the complex SCAP/SREBP in the endoplasmic reticulum, 
an integral-membrane protein termed Insulin induced gene-1 (Insig-1) and Insig-2 is 
bound to SCAP [173], [174], [175], [176]. 
Insig-1 and -2 are expressed in most tissues of the body with especially high 
expression in the liver [176]. Although they lack a traditional endoplasmic reticulum 
retention signal, Insigs are almost exclusively localized to the endoplasmic reticulum 
irrespective of sterol levels [176].  
There are important differences between the two Insig proteins: (i) Insig-1 is encoded 
by a gene that is transcriptionally activated by nSREBP (but the gene encoding insig-
2 is not) and (ii) Insig-1, has the ability to bind to the SCAP/SREBP complex even in 
the absence of sterol, whereas the interaction between Insig-2 and SCAP absolutely 
requires the presence of sterols [175], [177], [176]. Additionally, Insig-1 appears to 
bind SCAP with a slightly higher affinity than Insig-2, under normal conditions [178]. 
Finally, Insig-1 overexpression is positively controlled by nSREBP while Insig-2 
expression is negatively regulated by insulin [179] Importantly, SCAPs with point 
mutations at any one of multiple positions within the cholesterol-sensing domain 
cannot bind Insig proteins and facilitate SREBP processing even in the presence of 
elevated sterol levels [157]. Cholesterol addition to the endoplasmic reticulum 
membranes causes a conformational change in the cytoplasmic loop between the 
sixth and seventh membrane-spanning segments of SCAP [171], and the amount of 
cholesterol required to produce this conformational change is reduced in the 
presence of Insig proteins [172], thus facilitating the retention of SCAP/SREBP 
complexes in the endoplasmic reticulum. Sterol-insensitive SCAP mutants do not 
undergo this sterol-induced conformational change. The role that Insigs plays in the 
retention of SCAP/SREBP complexes is still not fully understood. It seems that the 
binding of Insigs to SCAP in the presence of sterols, when SCAP conformation is 
changed, simply prevents the binding of the COPII proteins Sec23/24 and the 
formation of SCAP/SREBP-containing COPII vesicles, that are used to exit the 
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endoplasmic reticulum for the Golgi apparatus. 
Exit of the endoplasmic reticulum via COPII vesicles 
In sterol-depleted cells, the SCAP/SREBP complex clusters laterally with other 
proteins into COPII-coated vesicles that bud from the endoplasmic reticulum [180], 
[181], [182], [183] (Fig. 19). COPII binding requires the sequence MELADL between 
the transmembrane region 6 and 7 in SCAP [183]. Like other proteins that cluster into 
COPII-coated vesicles [180], 
clustering of the SCAP/SREBP 
complex is initiated by Sar1, a small 
GTPase that binds to endoplasmic 
reticulum membranes in a GTP-
dependent fashion [182] (Fig. 19). 
Sar1 recruits a heterodimeric protein 
called Sec23/24, and this recruits 
another heterodimer, Sec13/31, 
which forms the coat of the COPII 
coated vesicle, thereby permitting 
vesicle budding (Fig. 19). Sec23/24 
binds to the SCAP/SREBP complex in 
a fashion dependent upon Sar1-GTP 
[182]. This binding did not occur when membranes contain a high sterol level, a 
condition in which the SCAP/SREBP complex does not move to the Golgi [182]. 
Instead, SCAP adopts a conformation in which the binding to Insig is preferred, 
ensuring the retention in the endoplasmic reticulum membrane [183]. 
 
This implies that the binding of Sec23/24 is itself not regulated by the conformation of 
SCAP, and this is supported by evidence that overexpression of SCAP results in 
SREBP processing irrespective of sterol concentration [184]. Additionally, Insig-1 has 
been shown to enhance the degradation of HMG-CoA reductase when sterol levels 
are high, by binding to its sterol-sensing domain [185], showing a dual role for Insigs 
in the SCAP/SREBP pathway and the regulation of cholesterol metabolism. 
From Goldstein et al . Cell (2006) 
Figure 19: Insig-mediated 
regulation of SCAP/SREBP 
transport. 
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Exit of the Golgi ,  on the route to the nucleus 
After processing of the SREBP precursor molecule the mature, active form of SREBP 
reaches its target compartment, the nucleus, where it activates genes involved in 
sterols and lipid synthesis. 
Proteins that are actively transported into or out the nucleus contain a nuclear 
localization signal (NLS) or a nuclear export signal (NES), respectively. The shuttling 
transport receptors bind their cargos via these signals on one side of the nuclear 
envelope, mediate their translocation through the nuclear pore complex (NPC) and 
then release them on the other side. The importin β superfamily regroups the family 
of transport receptor to or from the nucleus [186]. 
Nuclear import of classical NLS-containing proteins is initiated by binding to an 
importin α/β heterodimer [187]. Importin α directly interacts with the NLS as well as 
with importin β, and the resultant heterotrimer docks at the nuclear pore through the 
interaction of importin β with the NPC components [188], [189], [190], [191]. 
Subsequently, the docked complex is translocated through the NPC, via a pathway 
that is dependent of a small GTPase Ran and several Ran-interacting proteins [192]. 
The import reaction is terminated at the nucleoplasmic side of the NPC, where the 
binding of Ran-GTP to importin β causes the dissociation of the importin heterodimer 
[193], [194]. Thus, importin β acts as a receptor molecule for targeting to NPC and 
NPC translocation, whereas importin α acts as an adapter for karyophiles. Ran 
represents a key regulator of nucleocytoplasmic transport. 
Among the currently identified importin β-family members, only importin β uses an 
adapter, whereas the others directly bind to their cargos. However, importin β is also 
capable of binding directly to some nuclear proteins and to mediate their import. The 
ability of importin β to function without an adapter was first demonstrated for a fusion 
protein containing the importin β binding domain of importin β [194], [195].  
Importin β is now known to transport a wide variety of cargoes with distinct signal via 
direct interaction. These involves certain viral proteins, such as human 
immunodeficiency virus type 1 Tat and Rev, which are characterized by the presence 
of an arginin-rich NLS [196, 197]. Ribosomal protein rpL23a represents another class 
of substate, which contains an extremely basic import signal and can be imported 
also by other β-like transport receptor [198].  
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Nuclear import of the mature form of SREBP is carried out through the direct 
interaction with importin β in a ran-dependant manner. The importin β-binding domain 
is located on the bHLH-Zip domain of SREBP, which serves as an NLS [199, 200]. 
Dimerisation of SREBP is a 
prerequisite for its nuclear 
translocation [200]. Indeed, 
importin-β uses characteristic long 
helices like a pair of chopsticks to 
interact with an SREBP dimmer 
(Fig. 20). Importin-β changes its 
conformation to reveal a pseudo-
twofold symmetry on its surface 
structure so that it can 
accommodate a symmetric dimer 
molecule [201] (Fig. 20). 
Arriving in the nucleus: Specificity of  SREBP isoforms 
for target genes 
SREBPs directly activates more than 30 genes dedicated to the synthesis and uptake 
of cholesterol, fatty acids, triglycerides and phospholipids, as well as the NADPH 
cofactor required to synthesized these molecules and also glucose metabolism [152], 
[202], [203], [204].  
SREBP-1a is a potent activator of all SREBP-responsive genes, including those that 
mediate the synthesis of cholesterol, fatty acids, and triglycerides.  
The acidic transactivation domain is longer in SREBP-1a (of 29 amino acids) than in 
SREBP-1c, making SREBP-1a a stronger transcription activator [205]. Like SREBP-
1a, SREBP2 has a long transcriptional activation domain. 
The role of SREBP-1c and SREBP-2 are more restricted than that of SREBP-1a. 
SREBP-1c preferentially enhances the transcription of genes required for fatty acid 
synthesis but not cholesterol synthesis. Instead, SREBP2 preferentially activates 
cholesterol synthesis [152]. 
SREBP-1a is constitutively expressed in most tissues but at a low level [205]. Thus, 
SREBP1a probably have a role in maintaining basal levels of cholesterol and fatty 
From Lee et al., Science (2003) 
Figure 20: Cristal structure of 
importin-β binding to a dimer of 
SREBP2. 
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acid. SREBP-2 and -1a are the predominant isoforms of SREBP in most cultured cell 
lines, whereas SREBP-1c and -2 predominate in intact tissues with especially high 
levels in the liver, white adipose tissue, skeletal muscle, adrenal gland and brain 
[143].  
SREBP-2 responsive genes in the cholesterol biosynthetic pathway include those for 
the enzymes HMGCoA-synthase, HMGCoA-reductase, farnesyl diphosphate 
synthase, and squalene synthase. Using transgenic mice overexpressing SREBP2 
only, all the 12 enzymes involved in cholesterol biosynthetic pathway are induced, 
most notably the mRNA for HMGCoA reductase (75-fold) [204], [206] (Fig. 21). 
Enzymes for the cholesterol catabolism are not activated, such as acyl-
CoA:cholesterol acyltransferase that catalyses cholesterol ester formation [204] (Fig. 
21). SREBP-1c responsive genes include those for ATP citrate lyase (which 
produces acetyl-CoA) and acetyl-CoA carboxylase and fatty acid synthase (which 
together produce palmitate [C16:0]) (Fig. 21). Other SREBP-1c target genes encode 
a rate limiting enzyme of the fatty acid elongase complex, which converts palmitate to 
stearate (C18:0); stearoly-CoA desaturase, which converts stearate to oleate 
(C18:1); and glycerol-3-phosphate acyltransferase, the first committed enzyme in 
triglyceride and phospholipids synthesis [207], [203] (Fig. 21). SREBP-1c is also 
involved in the regulation of insulin-responsive genes, which control lipogenesis and 
glucose metabolism [208], [209], [210]. Finally, SREBP-1c and -2 activates 3 genes 
required to generate NADPH, which is consumed at multiple stages in these lipid 
biosynthetic pathways [211] (Fig. 21). 
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Interestingly, the preoteolytic activation of SREBP-1 and -2, respectively, can be 
regulated individually. For exemple, polyunsaturated fatty acids inhibit the proteolytic 
activation of SREBP-1 but, contrary to the action of oxysterols, they have no effect on 
SREBP-2 maturation [212]. In addition, glucose metabolites such as glucose-6-
phosphate may serve to accelerate maturation of SREBP1c only [213], but 
mechanistic details remains to be elucidated. 
Recognition of SREBP promoter:  Sterol Regulatory 
Element 
Unlike other bHLH-Zip transcription factors, which contain a well-conserved arginine 
residue in their basic domain, SREBPs have a tyrosine residue. This amino acid 
substitution confers flexibility and allows SREBPs to bind on both E-boxes (5’-
CANNTG-3’, where N represent any base) like all bHLH proteins, but also sterol 
regulatory element SRE sequences (5’-TCACNCCAC-3’) [214]. Mutation of the 
tyrosine residue into an arginine impairs binding of SREBPs to SRE [214]. All 
cholesterol-responsive promoters, including genes that regulate fatty acid as well as 
cholesterol metabolism, contain the direct repeat SRE site [215], that is not 
 
Figure 21: Genes regulated by SREBPs. 
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accessible to other bHLH-Zip proteins, thus ensuring highly regulated cholesterol-
dependent transcription. 
Additional coregulatory transcription factors are required for activation of the 
transcription (Fig. 22). Indeed, SREBPs are inherently weak activators by themselves 
and function synergistically with ubiquitous factors such as nuclear factor-Y (NF-Y) 
[216], camp response element binding protein (CREB) [217] and Sp1 [215] that bind 
in close proximity to achieve a high level of promoter activation [215], [218]. NF-Y 
interacts directly with SREBP [216] and Sp1 can stabilize the complex [219]. It 
appears that the promoters of different SRE-activated genes respond to different 
combinations of these transcription factors. Once a stable complex is formed in a 
promoter region, additional factor such as CREB binding protein (CBP) [220], [221], 
activated recruited cofactors (ARC) [222], ARC105 [146], vitamin D receptor 
interacting protein (DRIC) [222] or TATA binding protein (TBP)-associated factors 
may be recruited to initiate 
transcription (Fig. 22). 
Histone acetylation is also 
required for full 
transcriptional activity [223]. 
Such a complex has been 
shown to exist with SREBP-
1a and SREBP-2 but not with 
SREBP-1c. This is another 
explanation for the weak 
potency to activate the SRE 
gene battery.  
Other ways to regulate SREBP 
transcription factors 
SREBP transcription factors are regulated at three major levels: (1) transcription, (2) 
proteolytic cleavage of SREBP precursors and (3) post-translational modification of 
nSREBPs. Although there are some overlaps of regulatory mechanism across 
SREBP isoforms, significant differences do exist. In particular, whereas SREBP-1a 
Figure 22: SREBP complex for full gene 
activation. 
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and SREBP-2 appear to be predominantly regulated at the level of precursor 
cleavage, evidence suggests that SREBP-1c is mainly regulated at the transcriptional 
level. 
Transcriptional  control 
Both SREBP-1c and -2 contain SREs in their enhancer/promoter regions, thus the 
nuclear forms of SREBPs can activate their own genes in an autoregulatory loop 
[224], [147]. On the contrary, SREBP-1a appears to be constitutively expressed, 
albeit at a low level [225].  
SREBP-1c is regulated according to the diet but this induces only minor changes in 
other forms of SREBPs [226]. SREBP-1c expression is known to be regulated by at 
least 4 factors of central importance to the role of SREBP-1c in lipogenesis. These 
include polyunsaturated fatty acids [227] (which down regulates mRNA of SREBP-1a 
and -1c and prevent proteolytic processing [228]), the liver activated receptor α and β 
(LXRs) [229], insulin [215] (which induces SREBP-1c by binding to the SRE motif of 
the promoter of SREBP-1c [230]), and glucagon [231], [232] (which decrease mRNA 
abundance and lipogenesis [233]).  
LXR is a nuclear hormone receptor that is activated by oxysterols (derivates of 
cholesterol) [234, 235]. This transcription factor induces the expression of a range of 
genes involved in cholesterol efflux and clearance [236]. 
Glucose also induces transcription and proteolytic activation of SREBP-1c. [231], 
[232]. 
Post-translational modifications of SREBPs 
Inside the nucleus, the transcriptional activity of nSREBP is regulated by covalent 
modifications or by interaction with other proteins. Insulin stimulates the 
transcriptional activity of nSREBP-2 and nSREBP-1a through a mitogen-activated 
protein kinase (MAPK) pathway [237], [238]. The Ser-117 residue has been identified 
as the major phosphorylation site for MAPK in SREBP-1a [238]. Ser-432 and Ser-455 
are described as the Erk-MAPK phosphorylation sites [239] in vitro and in vivo in 
SREBP-2. These phosphorylations do not modify DNA binding but enhance SREBP-
2 transactivation capacity. Recently, phosporylation on SREBP-1 by the cAMP-
dependant kinase PKA, which is involved in lipid metabolism, has been shown to 
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greatly suppress SREBP-1 transactivation, revealing an inhibitory effect on SREBP-
mediated lipogenesis [240]. 
In the nucleus, nSREBPs are modified by ubiquitination and rapidly degraded by the 
26S proteasome as a consequence of their transcriptional activity [241], [242]. In the 
presence of the proteasome inhibitors ALLN and lactacystin, nSREBPs are stabilized 
and expression of their target genes is enhanced. 
After phosphorylation of SREBPs the ubiquitin ligase Fbw7 is recruited to SREBP 
molecules associated with target promoters. Fbw7-mediated ubiquitination of 
SREBPs is dependent on its DNA binding activity [243], [244], [242].  
SREBP-1 and SREBP-2 are also modified by the small ubiquitin-related modifier 
(SUMO)-1. SREBP-1a and SREBP-2 contain two and one sumoylation sites 
respectively. Sumoylation of SREBPs does not affect ubiquitination and thus the 
stability of the proteins but instead represses their transcriptional activities [245]. 
Interaction of SREBP-1a and SREBP-2 with the transcriptional activator p300 results 
in acetylation of SREBPs. Acetylation of lysine residues in SREBP-1a and SREBP-2 
enhances the stability of these transcription factors. In SREBP-1a, the acetylation-
binding site has been mapped to a specific lysine residue (Lys-333) in its DNA 
binding domain. This site was identified previously as an ubiquitination site and thus 
acetylation stabilizes SREBP-1a by preventing ubiquitination on the same residue. 
Mutant cel ls with defects in processing 
of SREBPs 
Two types of regulatory mutants in sterol metabolism have been isolated in 
appropriate selective media: (1) sterol-resistant cells, like the 25-RA cells, that fail to 
suppress enzymes of cholesterol synthesis or LDL receptors in response to 
cholesterol or oxygenated sterols such as 25-hydroxycholesterol; and (2) cholesterol 
auxotroph, which fail to induce the enzymes of cholesterol synthesis or LDL receptors 
upon sterol deprivation. Both of these phenotypes result from defects in regulation of 
SREBP cleavage. All those cell lines have been established and characterized in a 
Chinese hamster ovarian (CHO) cell line. 
The sterol-resistant mutants are divided into two classes. Class 2 includes the 25-RA 
cells and other CHO cell lines that produce a dominantly acting mutant SCAP. Class 
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1 mutants are sterol resistant because they produce a non-suppressible form of 
SREBP-2 that is truncated at residue 460, which is between the bHLH-Zip domain 
and the first transmembrane segment. The mutant cell lines of this class all have 
undergone recombinations in the intron following the exon that terminates at codon 
460 of SREBP-2 [153] and [246]. The resulting mRNAs encode fusion proteins 
whose SREBP-2 sequence terminates at codon 460. Since these proteins are never 
attached to membranes, they proceed to the nucleus directly without requiring 
proteolysis. Thus, they are immune from sterol down-regulation, and they confer a 
sterol-resistant phenotype. Each of these mutants involves SREBP-2, and not 
SREBP-1. 
The other type of CHO cell mutant is the cholesterol auxotroph mutants. The original 
cell line with this phenotype, M19 cells, was isolated by Chin and Chang [247] Those 
cells are deficient in site 2 protease, thus they are unable to release the active NH2-
terminal fragment of SREBPs from cell membrane of endoplasmic reticulum [248]. 
Cholesterol auxotrophic M19 CHO cell line [247], [249] (above) exhibited normal 
cleavage of SREBPs at site 1 following sterol deprivation. However, cleavage at site 
2 did not follow, and the NH2-terminal fragments of SREBPs accumulated in the 
membrane-bound intermediate form of the approximate size of the nSREBPs. The 
defect in M19 cells is recessive and can be corrected by transfection of the S2P gene 
[250], [248].  
Later, other cell types: SRD-12B and SRD-12A have been identified by Rawson et al. 
[251], for auxotrophy in cholesterol. Those cell types are deficient in site 1 protease. 
This deficiency can be corrected by recomplementation with the human S1P gene 
[154]. As the cleavage of S1P is a prerequisite for the cleavage by S2P, SREBPs 
molecules remain in the endoplasmic reticulum in the precursor form.  
These cells were shown to have three phenotypic abnormalities: (1) failure to induce 
cholesterol biosynthetic enzymes such as HMGCoA synthase and HMGCoA 
reductase upon sterol deprivation, thus explaining the cholesterol auxotrophy; (2) 
failure to induce the LDL receptor, indicating that the cells have a global failure to 
induce sterol-repressed genes upon sterol deprivation; and (3) a requirement for 
unsaturated fatty acids, in addition to cholesterol, for cell growth. 
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Aim of the study 
 
Pathogenic micro-organisms, and in particular bacteria, often produce pore-forming 
proteins as virulence factors. In vitro, the most common outcome is cell death. It is 
however becoming apparent that cells respond to pore formation in a manner that 
may allow survival of the cell or the organ, in vivo.  
With the aim of understanding cellular responses to PFTs, we made use of the well-
characterized toxin aerolysin and adopted a global approach. Genes that are 
differentially expressed upon toxin treatment of cells were identified using an RNA 
differential display (ADDER) technique. This strategy led us to the identification of a 
potentially interesting candidate: SREBP2, a key regulator in cholesterogenesis and 
lipidogenesis. 
We then focused our study on the involvement of SREBPs and the subsequent 
upregulation of lipid metabolic pathways in cell survival. 
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INTRODUCTION 
Pathogenic micro-organisms, and in particular bacteria, often produce pore-forming 
proteins as virulence factors [252]. These proteins are either bonafide pore-forming 
toxins or components of type III secretion apparatus involved in perforating the host 
plasma membranes to allow the injection of bacterial effectors necessary for infection 
[253]. The size of the pores varies from 1-2 nm for pore-forming toxins such as 
aerolysin from Aeromonas hydrophila [254] or α-toxin from Staphylococcus aureus 
[255], to 25-30 nm for Cholesterol Dependent Toxin such as pneumolysin or 
listeriolysin O [256]. Depending on the toxin, its concentration and the type of target 
cell, the outcome of the toxin induced plasma membrane perforation may also vary. 
The two extreme cases are osmotic lysis of erythrocytes, which are not necessarily 
physiological targets of these toxins, and full membrane repair and cell survival as 
observed at low doses of certain toxins [130, 257]. The most common outcome in 
vitro is however cell death –which can be apoptotic or necrotic, but has generally not 
been characterized [254]. Little is known however about the underlying cellular 
mechanisms. 
Here we were interested in understanding cellular responses to pore-forming 
toxins, in particular survival mechanisms. We used aerolysin as a prototype since it is 
well characterized [254] and a variety of inactive mutants are available [76, 99]. The 
toxin is secreted by Aeromonas species as an inactive precursor, called proaerolysin, 
which must be proteolytically processed by gut enzymes or by proteases of the furin 
family [254]. The precursor, as well as the mature toxin, binds specifically to GPI-
anchored proteins at the surface of target cells [254]. Once bound and processed, 
the toxin heptamerizes into a circular ring, a process that is promoted by lipid rafts 
[111]. Toxin oligomerization leads to the exposure of hydrophobic surfaces that drive 
membrane insertion [87]. Pore-formation renders the plasma membrane permeable 
to small ions –but not proteins [254]. Specific cellular effects observed upon aerolysin 
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treatment are release of calcium from the endoplasmic reticulum (ER), vacuolation of 
the ER [254] and production of proinflammatory molecules such as Tumor Necrosis 
Factor α (TNFα), interleukin 1ß, interleukin 6 and prostaglandin E2 [73, 134]. We 
show here that, by allowing the efflux of intracellular potassium, aerolysin triggers the 
activation of caspase-1. This cysteine protease is produced as a 45 kDa precursor 
that requires autocatalytic processing for activation. Autoproteolysis depends on the 
formation of a large multiprotein oligomeric complex, called the inflammasome [17], 
which brings pro-caspase-1 molecules in close proximity of one another. Two types 
of inflammasomes have been reported, each containing a different member of the 
intracellular pattern recognition receptors, the so-called NLR (NACHT-LRR) family of 
proteins [17]. NLR members are typically composed of 3 domains: a Leucine Rich 
Repeat (LRR) ligand sensing domain, a NACHT oligomerization domain, and a C-
terminal homotypic protein-protein interaction domain that can be either a CARD 
domain or a pyrin domain. Recently some natural stimuli of the inflammasomes have 
been identified, such uric acid crystals associated with Gout [33], bacterial RNA [32], 
extracellular ATP, calcium channel affecting marine toxin maitotoxin [31] and 
cytoplasmic flagellin [36, 37], leading to the view that inflammasomes are intracellular 
detectors of danger signals. Two NLR members can induce caspase-1 activation: 
NALP and IPAF. Genomic analysis has revealed 14 NALPs in the human genome of 
which NALP1 and NALP3 have been best characterized and shown to be involved in 
caspase-1 activation [258]. The interaction of NALPs with caspase-1 is not direct and 
depends on the adaptor protein ASC (apoptosis-associated speck-like protein 
containing a CARD) [17]. IPAF, for which only one form has been reported, in 
contrast associates directly with caspase-1 via its C-terminal CARD domain [17], 
although direct or indirect interactions with ASC may exist [28, 259].  
We here found that aerolysin-induced K+ efflux triggers the assembly of IPAF 
and the NALP3 inflammasomes and the activation of caspase-1. Most importantly, 
we found that caspase-1 then induces the activation of the central regulators of 
membrane biogenesis, the Sterol Regulatory Element Binding Proteins (SREBPs), 
which in turn promote cell survival upon toxin challenge. This study highlights that, in 
addition to its well established role in triggering inflammation via the processing of the 
precursor forms of interleukins 1ß, 18 [260] and 33 [51], caspase-1 has a broader 
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role than previously appreciated, in particular linking the intracellular ion composition 
to lipid metabolic pathways. 
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RESULTS AND DISCUSSION 
Pore-formation by aerolysin leads to 
the activation of SREBPs 
To study the cellular response to pore-forming toxins, we performed an RNA 
differential display analysis using the highly sensitive ADDER (Amplification of 
Double-stranded cDNA End Restriction fragments) method [261]. CHO cells were 
treated with low concentrations of proaerolysin (0.1 nM, [262], conditions under which 
all cells excluded the DNA intercalating agent propidium iodide for at least 10 hrs 
(Suppl. Fig. 1A) (note that the protoxin is processed to aerolysin by cell surface 
proteases, leading to pore formation). The ADDER analysis led to the identification of 
various differentially expressed genes, in particular the Sterol Regulatory Element 
Binding Protein 2 (SREBP2) which was upregulated after 3 hrs (Suppl. Fig. 1B). 
SREBPs are membrane bound transcription factors that regulate the expression of 
genes harboring a Sterol Responsive Element (SRE) in their promoter region and 
which are typically involved in cholesterol and fatty acid biosynthesis (for review see 
[263]. SREBPs initially reside in the ER. Release of the transcription factor domain 
from the membrane requires sequential proteolysis by two transmembrane 
proteases, S1P and S2P, which reside in the Golgi apparatus. Cleavage of SREBPs 
thus requires transport of the protein from the ER to the Golgi, a step that is 
controlled by the escort protein SCAP [263]. Three major SREBP isoforms are known 
in human and hamster: SREBP1a and 1c which are encoded by a single gene and 
SREBP2 which is encoded by a distinct gene. SREBP1 is preferentially involved in 
fatty acid metabolism, and SREBP2 in cholesterol and lipid biosynthesis [263, 264]. 
Different stimuli have been reported to induced SREBP activation including 
cholesterol depletion [263], ER calcium depletion [265], growth factors and insulin 
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signaling [266, 267], phagocytosis [268] and exposure of cells to a hypotonic medium 
[265]. 
Since the main regulatory mechanism of SREBPs occurs at the protein level, 
rather than the transcriptional level, we tested whether aerolysin triggers SREBP2 
processing. Membrane and nuclear fractions were prepared from toxin-treated cells 
and probed by Western blotting using an antibody against the N-terminus of 
SREBP2. In untreated cells, full-length SREBP2 (123 kDa) was found in the 
membrane fraction (Fig. 2.1A), as expected since cells were grown in the presence of 
serum, the high lipid content of which suppresses SREBP activation. Upon aerolysin 
treatment, the amount of full length SREBP2 decreased with time with the 
concomitant appearance of an ≈ 60 kDa form in the nuclear fraction. Migration of 
SREBP2 to the nucleus was confirmed by immunofluorescence microscopy (Fig. 
2.1B). Interestingly, the second SREBP isoform, SREBP1, also underwent activation 
upon toxin treatment (Fig. 2.1C). These results show that aerolysin caused the 
proteolytic processing and nuclear translocation of SREBPs.  
We next measured the effect of aerolysin on the mRNA levels of two SREBP 
target genes: HMGCoA reductase and fatty acid synthase activated by SREBP2 and 
SREBP1 respectively [264]. Both mRNAs were increased by toxin addition as shown 
by real-time PCR (fig. 2.1DE, >3 fold after 3hrs). Also the total cellular cholesterol 
increased by 25 to 30% after 3 to 5 h toxin treatment (Fig. 2.1F). Similar increases 
were observed whether cells were incubated in serum free medium or in serum 
containing medium, in the presence or absence of the cholesterol synthesis inhibitor 
lovastatin (not shown) indicating that cholesterol could be synthesized as well as 
taken up from the medium, in agreement with the regulatory effect of SREBP2 on 
transcription of the LDL receptor gene.  
Altogether these observations show that aerolysin triggers the activation of 
SREBPs, the subsequent upregulation of genes under the control of Sterol 
Regulatory Elements and the increase of cellular cholesterol. 
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Figure 2.1: Figure 1: Aerolysin triggers the activation of SREBPs. 
A- CHO cells were treated or not for 1, 2 or 3 hours with 0.2nM proaerolysin. A 
membrane fraction and a nuclear extract were prepared and 80µg of each 
fraction were analyzed for the presence of SREBP-2 by western blotting. B- 
Immunofluorescence against SREBP2 of CHO cells treated with 0.2nM aerolysin 
for 3 h. Bar: 10 µm. C- CHO cells were treated as in A and cellular fractions 
were probed for SREBP-1 by western blotting. D, E- RNA was extracted from 
CHO cells treated or not with 0.2nM proaerolysin for 1, 3 or 5 hours. Levels of 
HMGCoA reductase (D) and fatty acid synthase (E) mRNAs were quantified by 
real-time PCR analysis and normalized to the levels of mRNAs of translation 
elongation factor 1 α1 and of the transcription factor TATA Binding Protein which 
did not significantly change upon toxin treatment. Error bars represent standard 
deviations (n=3). F- CHO cells were treated as in A and the cellular cholesterol 
levels were determined as described in Experimental Procedures and normalized to 
the protein concentration.  
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Toxin induced K+  efflux triggers 
SREBP2  activation 
To understand the mechanisms that mediate aerolysin-induced SREBP activation, 
we first investigated whether pore-formation was required by using two hemolytically 
inactive aerolysin mutants: ASSP, which binds to GPI-anchored proteins but is 
unable to form heptamers [99], and Y221G, which binds to GPI-anchored proteins, 
forms heptamers but is unable to insert into membranes [76]. Neither mutant affected 
SREBP2 indicating that pore-formation is necessary for activation of the transcription 
factor (Fig. 2.2A). Since the same purification procedure was used for WT and 
mutant toxins, these observations also indicate that aerolysin-induced SREBP 
activation is not due to contaminating bacterial products and in particular 
lipopolysaccharide (LPS). This was confirmed by the lack of effect of LPS binding 
antibiotic polymixin B on aerolysin-induced SREBP2 activation (Suppl. Fig. 2A). Pore-
formation per se thus appeared to be required for SREBP2 activation. We thus 
wondered whether another pore forming toxin would trigger the same lipogenic 
response, and α-toxin form Staphylococcus aureus was chosen since its mode of 
action and pore size are very similar to that of aerolysin [255]. In HeLa cells (CHO 
cells are insensitive to α-toxin), both aerolysin (see Fig. 2.3A) and Staphylococcal α-
toxin induced SREBP2 activation (Fig. 2.2B). 
Since SREBP2 is an ER membrane protein and since we have previously 
shown that aerolysin triggers fragmentation and vacuolation of the ER [90], we 
investigated whether SREBP2 activation was due to toxin induced ER alterations. 
Vacuolation can be prevented either by the addition of sucrose to the medium 
(unpublished) or by chelating extracellular calcium [90]. Neither sucrose (Suppl. Fig. 
2B), nor EGTA (Suppl. Fig. 2C) in the extracellular medium prevented SREBP2 
activation. These experiments moreover indicate that SREBP2 activation is not due 
to entry of extracellular calcium. A role of elevated intracellular calcium was further 
ruled out by the use of the intracellular calcium chelator BAPTA-AM, which had no 
effect on SREBP2 activation (not shown).  
We then tested whether exit of potassium, through the toxin pores, could be the 
trigger for SREBP2 activation. Cells were treated with aerolysin in a high (150 mM 
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KCl) or low (5 mM KCl) K+ containing medium, or in tissue culture medium 
(containing serum). No K+ efflux was observed upon toxin treatment in high K+ 
medium (not shown), as expected, but, remarkably, SREBP2 was no longer activated 
(Fig. 2C). These observations suggest that K+ efflux was necessary. To test whether 
K+ efflux was sufficient for SREBP2 activation, cells were treated with the K+ 
ionophore valinomycin. As shown in Fig. 2D, valinomycin led to a similar proteolytic 
activation of SREBP2. In contrast monensin, a sodium ionophore (which was active 
under our experimental conditions, Suppl. Fig. 2.3), had no effect (not shown) 
suggesting that activation of SREBP2 is due to potassium efflux and not membrane 
depolarization. 
It has previously been reported that thapsigargin induced ER calcium release 
leads to SREBP activation [265]. Although aerolysin also leads to ER calcium release 
[125], this event is not necessary for K+ efflux-mediated SREBP2 activation since 
valinomycin, which efficiently triggers SREBP2 activation, has no effect on ER 
calcium (not shown).  
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Figure 2.2: Aerolysin induced potassium efflux triggers both SREBP2 
maturation and inflammasome-mediated activation of Caspase-1. 
A- CHO cells were treated or not with 0.2 nM WT or mutant aerolysins, ASSP 
and Y221G, for 3hrs. Membrane and nuclear fractions were analyzed (80 µg) by 
Western blotting against SREBP-2. B- HeLa cells were treated for different 
times with Staphylococcal α-toxin (30 nM). Membrane and nuclear fractions were 
analyzed (80 µg) by Western blotting against SREBP-2. C- CHO cells, in tissue 
culture medium (Culture), Hanks buffer (low K+) or a modified Hanks buffer in 
which the sodium and potassium concentrations were inverted (High K+), were 
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treated or not with 0.2 nM proaerolysin for 3hrs. Cellular fractions were 
subsequently analyzed as in A. D- CHO cells were treated for different times 
with 10 µM of valinomycin. Cellular fractions were subsequently analyzed as in A. 
E, F- CHO cells were treated or not with 0.2 nM WT or Y221G mutant 
proaerolysin or 10 µM of valinomycin for 3hrs in either tissue culture medium 
(Culture, cult.), Hanks buffer (low K+) or High K+ as in C.  Activation of caspase-1 
was monitored either (E) by western blotting to detect processing of the 45 kDa 
pro-caspase-1 or (F) using the fluorescent reagent, FLICACasp1, which labels active 
caspase-1. FLICACasp1 was added to the culture medium during the last hour of 
toxin incubation. Cells were then washed and the number of FLICACasp1 positive 
cells determined by FACS analysis. G- HeLa cells were transiently transfected 
(24h) with RNAi duplexes against ASC, NALP3 and IPAF in single to triple 
transfections. Two duplex sequences, labeled 1 and 2, were used for NALP3 and 
IPAF. Cells were then treated with proaerolysin for 3 h at 0.2 nM. During the 
last hour of toxin incubation FLICACasp1 was added to the culture medium. Cells 
were then washed and the number of FLICACasp1 positive cells determined by FACS 
analysis. Under each RNAi condition, the number of FLICACasp1positive cells in the 
absence of toxin was extremely low and thus not visible on a y-axis ranging from 
0 to 80%. 
Aerolysin triggers inflammasome-
mediated activation of Caspase-1  
The above experiments show that the event that is sensed upstream of SREBP 
activation is the loss of intracellular K+. Potassium efflux, triggered by Staphylococcal 
α-toxin [269], K+ ionophores [31, 270] or activation of the P2X7 receptor by 
extracellular ATP [271]; Mariathasan, 2006 #3151}, has been shown to activate 
caspase-1. We therefore analyzed the effect of aerolysin on caspase-1. As shown in 
Fig. 2.2E, WT, but not Y221G mutant, aerolysin led to the processing of pro-caspase-
1. Caspase-1 cleavage was however only observed when extracellular K+ was low 
(Fig. 2.2E) indicating that K+ efflux was necessary and indeed caspase-1 activation 
could also be triggered by valinomycin (Fig. 2.2E). Identical observations were made 
when using the commercially available fluorescent reagent, FLICACasp1 that binds to 
the active form of caspase-1 with high affinity (Fig. 2.2F). Importantly caspase-1 
activation was equally observed with polymixin B treated WT aerolysin, ruling out a 
role of contaminating LPS (Suppl. Fig. 4A). Finally aerolysin specifically activated 
caspase-1, since caspase-3 was not activated as monitored by western blotting (not 
shown) or using the caspase-3 specific FLICA Casp3 reagent (Suppl. Fig. 4B).  
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To investigate whether the inflammasomes are involved in sensing the 
aerolysin-induced K+ efflux, we silenced expression of IPAF, NALP3 and/or ASC by 
siRNA. All duplex RNAis (two for IPAF and NALP3 and 1 for ASC) efficiently reduced 
the levels of the corresponding mRNAs (Suppl. Fig. 5A) as well as the expression of 
the corresponding FLAG tagged proteins (Suppl. Fig. 5B). Interestingly, knock down 
of ASC, NALP3 or IPAF individually led to a 30 to 50% decrease in the number of 
cells in which caspase-1 was activated in response to aerolysin (Fig. 2.2G), whereas 
the transfection of 4 different irrelevant siRNAs had no effect (Suppl. Fig. 6A). 
Double-transfection with siRNA against ASC and NALP3 did not lead to a further 
decrease, whereas knocking down ASC and IPAF together essentially abolished 
caspase-1 activation as did triple transfection against all three components (Fig. 
2.2G). Again triple transfection using irrelevant siRNAs had no effect (Suppl. Fig. 6A). 
The inhibitory effect of these siRNAs were specific for inflammasome mediated 
pathways since co-transfection of siRNAs against ASC and IPAF for example did not 
prevent activation of the interferon ß pathway by Sendai virus [272] (Suppl. Fig. 7). 
These results show that aerolysin induces activation of caspase-1 through the 
assembly of both the IPAF and the NALP3 inflammasomes. It is interesting to note 
that toxin induced K+ efflux is to our knowledge the first stimulus that simultaneously 
activates both inflammasomes, raising the possibility that for such a severe stress, 
nature has conceived a backup pathway. 
Aerolysin induced SREBP activation is 
caspase-1  mediated 
Aerolysin-induced K+ efflux triggers activation of both caspase-1 and SREBP2. To 
determine whether these events lie in a common pathway or not, we investigated 
whether preventing one would affect the other. Remarkably, the caspase-1 inhibitor 
YVAD completely blocked aerolysin-induced SREBP2 activation (Fig. 2.3A left 
panel), whereas the caspase-3 inhibitor DEVD had no effect (not shown). Aerolysin-
induced SREBP2 activation could also be prevented by knocking down the 
inflammasomes using siRNAs against NALP3, ASC and IPAF (Fig. 2.3A, right panel) 
or by knocking down directly the expression of caspase-1 (Fig. 2.3B, left panel). This 
effect was specific to caspase-1, since RNAi against caspase-3 had no effect (Fig. 
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2.3B, left panel). RNAi against caspase-1, but not caspase-3, also prevented 
aerolysin-induced activation of SREBP-1 (Fig. 2.3B, right panel). These observations 
show that caspase-1 activation lies upstream, and is required for, SREBP activation. 
In agreement with this sequence of events, preventing activation of SREBP2 (see 
methods below) had no effect on aerolysin-induced caspase-1 activation (Suppl. Fig. 
9B). 
Figure 2.3: Aerolysin-induced SREBP activation is caspase-1 
dependent but S1P and S2P mediated. 
A- Left panel, CHO cells were treated or not with the caspase-1 inhibitor YVAD 
(100µM) for 1h, followed by 3hrs with proaerolysin (0.2 nM), still in the presence 
or absence of inhibitor. Membrane and nuclear fractions were prepared and 
analyzed (80 µg) for the presence of SREBP-2 by Western blotting. Right panel, 
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HeLa cells were transiently transfected (24h) with RNAi duplexes against ASC, 
NALP3 (sequence 1) and IPAF (sequence 1) followed by 3hrs treatment with 0.2 
nM proaerolysin. Membrane and nuclear fractions were prepared and analyzed (80 
µg) for the presence of SREBP-2 by Western blotting. B- HeLa cells were 
transiently transfected (24h) with RNAi duplexes against caspase 1 or 3 followed 
by 3hrs treatment with 0.2 nM proaerolysin. Membrane and nuclear fractions (80 
µg) were analyzed for the presence of either SREBP-2 (left panel) or SREBP-1 
(right panel) by Western blotting. C- CHO cells were treated either with β-
methyl-cyclodextrin (ßMCD, 10mM) in a serum free medium for 1h or with 0.2 nM 
proaerolysin for 3hrs. Nuclear fractions (80 µg) and SREBP-2 was detected by 
Western blotting. D- HeLa cells were transiently transfected (48h) with RNAi 
duplexes against SCAP, S1P or S2P followed by 3hrs treatment with 0.2 nM 
proaerolysin. Membrane and nuclear fractions (80 µg) were analyzed for the 
presence of SREBP-2 by Western blotting. E- S1P or S2P deficient CHO cells and 
the corresponding recomplemented CHO were treated with 0.2 nM proaerolysin 
for 3hrs. Membrane and nuclear fractions (80 µg) were analyzed for the 
presence of SREBP-2 by Western blotting. Two different exposures of the 
membrane fraction are shown. 
 
Capase-1  triggers S1P and S2P mediated 
SREBP activation 
Since caspase-1 is a protease and since activation of SREBPs involves proteolysis, 
we investigated the possibility of a direct activation. Hamster SREBP1 and 2 each 
contain a potential caspase-1 cleavage site in their N-terminal cytoplasmic region that 
would lead to a 3 kDa and 27 kDa form respectively. These forms would however not 
contain the helix-loop-helix DNA binding domain and thus be inactive. SREBPs in 
addition contain numerous aspartic acid residues at the amino side of the first 
transmembrane region, which could be unconventional caspase cleavage sites. We 
first compared the migration patterns of the nuclear forms of SREBP2 obtained 
through aerolysin activation of caspase-1 or by sterol deprivation. As shown Fig.2.3C, 
the migration pattern of SREBP2 was indistinguishable for cells treated with aerolysin 
or with the cholesterol extracting drug ß-methyl cyclodextrin (ßMCD) (4-12% 
acrylamide gradient gels were used to maximize the resolution in the 50 kDa size 
range) indicating that cleavage occurred at the same sites and thus possibly by the 
same enzymes. 
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To test whether aerolysin-induced activation of SREBP2 occurs via the well 
established SCAP, S1P and S2P dependent pathway [263], we performed RNAi 
against these three proteins (Suppl. Figure 8). Knocking down the escort protein 
SCAP or one of the two proteases prevented the aerolysin-induced activation of 
SREBP2 (Fig. 2.3D). To further strengthen the involvement of S1P and S2P, we 
made use of mutant CHO cell lines deficient in either of the proteases (S1P-/-, [251]; 
S2P-/-, [248]). The mature form of SREBP2 could not be detected in nuclear extracts 
of aerolysin-treated S1P-/- or S2P-/- cells, in contrast to the recomplemented cells (Fig. 
2.3E). SREBP2 remained full length in S1P-/- cells, whereas an intermediate, 
membrane bound form could be detected in S2P-/- cells consistent with a first 
cleavage event by S1P. Recomplementation of cells with the appropriate protease 
led to the recovery of toxin-induced SREBP2 activation. Altogether these 
observations show that SREBP2 activation induced by aerolysin depends on SCAP 
and the sequential processing by S1P and S2P. 
Toxin induced activation of the SREBP 
pathway promotes cell survival 
Having outlined a new signaling pathway linking toxin-induced membrane 
permeabilization to the activation of lipogenic genes, we investigated whether this 
pathway plays a role in cell survival. For this, we interfered with different steps along 
the pathway and monitored cell death by propidium iodide staining and FACS 
analysis. Aerolysin-induced K+ efflux was prevented by incubating cells in high K+ 
medium. Caspase-1 activation was prevented either by using a caspase-1 inhibitor or 
RNAi against various components of the inflammasomes including caspase-1 itself. 
SREPB2 activation was inhibited using 25-hydroxycholesterol (25OH-Chol), a well 
established inhibitor of SREBP activation [153], by overexpression of INSIG-1 [176, 
268], a multispanning membrane protein involved in the retention of SREBP2 in the 
ER [263], by RNAi against SCAP, S1P, S2P or directly against SREBP1 or 2. And 
finally, the effect of inhibiting enzymes upregulated by SREBPs was probed by using 
cerulenin, an inhibitor of fatty acid synthase [257]. 
 As shown in Fig. 2.4A, death was increased when cells were treated with 
aerolysin in a high potassium medium. Cell death was also promoted when the 
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NALP3 and IPAF inflammasomes where simultaneously knocked down by RNAi (Fig. 
2.4B), whereas RNAi against irrelevant proteins had no effect (Suppl. Fig. 6B). 
Knocking down one of the two inflammasomes however had no effect on cells death, 
conditions under which aerolysin induced caspase-1 activation was only moderately 
reduced (Fig. 2.2G). In agreement with the death promoting activity of the inhibitory 
RNAis, inhibition of caspase-1 using YVAD also led to an increase in cell death, 
whereas inhibition of caspase-3 had no effect (Fig. 2.4C). 
Figure 2.4: Preventing caspase-1 mediated SREBP2 maturation 
promotes aerolysin-induced cell death. 
A- CHO cells were incubated in tissue culture medium (Culture), or Hanks buffer 
(low K+) or a modified Hanks buffer in which the sodium and potassium 
concentrations were inverted (High K+). Cells were treated for 1 min with 
different concentrations of proaerolysin and then incubated in the corresponding 
medium for 4h prior to propidium iodide staining and FACS analysis. B- HeLa cells 
were transiently transfected (24h) with RNAi duplexes against ASC, NALP3 and 
IPAF in single to triple transfections. Two duplex sequences, labeled 1 and 2, 
were used for NALP3 and IPAF. Cells were then treated as in A. C- CHO cells 
were treated or not with either the caspase-1 inhibitor YVAD (100µM) or the 
 
 71 
caspase-3 inhibitor DEVD (100 µM) for 1h, followed by 3hrs with proaerolysin (0.2 
nM), then stained with propidium iodide and analyzed by FACS. 
  
 
We next inhibited aerolysin-induced activation of SREBP2 using 25OH-Chol. 
(Fig. 2.5A). This drug had no effect on the upstream events such as the kinetics of 
pore formation by aerolysin (Suppl. Fig. 9A) or the activation of caspase-1 (Suppl. 
Fig. 9B). Cell death was however strongly increased (Fig. 2.5B). This effect was 
specific to aerolysin-induced cell death since 25-OH cholesterol did not enhance 
death induced by the pro-apoptotic kinase inhibitor staurosporine (Suppl. Fig. 9C). 
Increased cell death was not due to the accumulation of toxic insults since 19OH-
cholesterol, which does not inhibits SREBP2 activation (Fig. 2.5B, [263], as well as 
two unrelated inhibitors of cellular activities, leupeptin which inhibits lysosomal 
enzymes and bafilomycin, which inhibits the vacuolar proton ATPase, had no effect 
on aerolysin-induced cell death (Fig. 2.5B and Suppl. Fig. 9D). 
As an alternative to 25-OH cholesterol, we overexpressed INSIG-1, which 
prevented SREBP2 activation both by sterol extraction with ßMCD (Fig. 2.5C, left 
panel, [263] and by aerolysin (Fig. 2.5C, right panel). As 25-OH cholesterol, INSIG-1 
overexpression had no effect on aerolysin-induced activation of caspase-1 (Suppl. 
Fig. 9B) but promoted toxin-induced cell death (Fig. 2.5D). Overexpression of two 
irrelevant proteins, the transmembrane influenza hemaglutinin or the green 
fluorescent protein, in the same expression vector had no effect (Suppl. Fig. 10). 
Finally, we investigated whether inhibiting an enzyme that is upregulated by SREBPs 
would influence cell death. Cerulenin, an inhibitor of fatty acid synthase [257], 
drastically enhanced aerolysin-induced cell death (Suppl. Fig. 11).  
Together these experiments show that interfering with SREBP activation and 
function promotes cell death in response to pore-formation by aerolysin. 
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Figure 2.5: Interfering with the SREBP pathway promotes aerolysin-
induced cell death. 
A, B- CHO cells were treated or not with 1µg /ml 25 hydroxycholesterol (25OH 
Chol.) or 19 hydroxycholesterol (19OH Chol.) for 1h at 37°C. A, Cells were 
additionally treated or not with 0.2 nM proaerolysin for 3hrs, in the presence or 
not of the drugs. Membrane and nuclear fractions were analyzed (80 µg) by 
Western blotting against SREBP-2. B- Cells were treated for 1 min with different 
concentrations of proaerolysin and then incubated in tissue culture medium, in the 
presence of the drugs, for 4h prior to propidium iodide staining and FACS analysis. 
C- HeLa cells overexpressing or not human INSIG-1 were treated or not with ß 
methylcyclodextrin (ßMCD, 10 mM) (left panel) or 0.2 nM proaerolysin for 3hrs 
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(right panel). Membrane and nuclear fractions were analyzed (80 µg) by Western 
blotting against SREBP-2. Total cells extracts were probed for myc-tagged 
INSIG-1. D- HeLa cells overexpressing INSIG-1 were treated for 1 min with 
different concentrations of proaerolysin and then incubated in tissue culture 
medium for 4h and analyzed as in B. E- HeLa cells were transiently transfected 
(48h) with RNAi duplexes against SREBP1, SREBP2 and SCAP. Cells were treated 
and analyzed as in B. F- S1P or S2P deficient CHO cells and the corresponding 
recomplemented CHO were treated and analyzed as in B. Inset: S1P or S2P 
deficient CHO cells and corresponding recomplemented cells were treated for 
3hrs with 0.2nM proaerolysin. FLICACasp1 was added to the culture medium during 
the last hour of toxin incubation. Cells were then washed and the number of 
FLICACasp1 positive cells determined by FACS analysis. 
 
Aeromonas-triggered caspase-1-
mediated SREBP2  activation promotes 
cell survival 
To test whether the here identified caspase-1-dependent SREBP2 activation pathway 
operates during infection by a ß-hemolytic bacterium, primary human fibroblasts were 
infected with Aeromonas trota, an aerolysin producing species responsible for severe 
diarrhea in humans [74]. The bacterium triggered massive activation of caspase-1, in 
a strictly aerolysin dependent manner as demonstrated using the same Aeromonas 
strain in which the aerolysin gene had been selectively inactivated (Fig. 2.6A). 
Infection of these primary cells with the WT Aeromonas trota strain also led to a 
strong activation of SREBP2, whereas the aerolysin deficient strain had no effect 
(Fig. 2.6B). Finally, wild type Aeromonas, but not the aerolysin deficient strain, 
induced cell death and death was increased in 25-OH cholesterol treated cells (Fig. 
2.6C). Altogether these observations indicate that during infection, pore-formation by 
aerolysin leads to the activation of caspase-1 and the subsequent processing and 
nuclear translocation of SREBP2 and that activation of this pathway promoted cell 
survival. 
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Figure 2.6: Aeromonas trota triggers 
caspase-1 mediated SREBP2 activation 
in primary human fibroblasts. 
Primary human fibroblasts were infected 
with wild type (AerA+) or aerolysin deficient 
(AerA-) Aeromonas trota at an MOI of 1.5 
or treated with 0.2 nM proaerolysin. A, 
FLICACasp1 was added to the culture medium 
after 2 hrs. One hour later, cells were 
washed and the number of FLICACasp1 positive 
cells determined by FACS analysis. B, Cells 
were harvested after 3 hrs. Membrane and 
nuclear fractions were prepared and 
analyzed (80 µg) for the presence of 
SREBP-2 by Western blotting. C, Cells were 
treated or not with 1µg /ml 25 
hydroxycholesterol (25OH Chol.) for 1h at 
37°C and then infected as in A. After 3 hrs, 
cells were incubated with propidium iodide 
and the number of positive cells was 
quantified by FACS analysis. 
 75 
CONCLUDING REMARKS 
Here we have identified a novel signaling pathway that links changes in 
cytoplasmic ion composition, due to plasma membrane permeabilization, to lipid 
metabolism and cell survival. Although many details remain to be elucidated, our data 
indicate that, in response to a drop in cytosolic [K+], the following sequence of events 
is triggered (Fig. 2.7). The drop in intracellular [K+] activates the IPAF and 
ASC/NALP3 inflammasomes and allows the processing of caspase-1. Whether the 
LRR domains of IPAF and NALP3 are the direct sensors of the [K+] decrease remains 
to be shown. Once activated, caspase-1 induces the processing of SREBPs by 
acting on an intermediate target, which then induces the processing of SREBPs by 
S1P and S2P. Mature SREBPs is transported into the nucleus leading to the 
upregulation of lipogenic genes [263]. All the means we have used to interfere with 
SREBP activation or lipid biosynthesis –RNAi against the inflammasomes, caspase-1 
or SREBPS themselves, 25OH-cholesterol treatment, INSIG-1 over expression or 
inhibition of fatty acid synthase– all led to an increase in toxin-induced cell death 
indicating that lipid biosynthesis is important for cell survival in response to pore-
formation. 
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 The present work highlights that caspase-1 may have a far broader role than 
until now appreciated. In addition to its well-established roles in the production of 
proinflammatory cytokines [260] and in the initiation of cell death upon infection by 
certain pathogens (for review see [273], caspase-1 may be equally important in 
promoting survival upon pathogen attack as well as having a more general role as a 
positive regulator of lipid metabolism. To fulfill these additional roles, caspase-1 must 
modify target proteins other than the precursor forms of interleukins 1ß, 18 and 33. 
The identification of these targets will clearly be of an important future challenge.  
 
Figure 2.7: Toxin-induced changes in cytoplasmic 
ion composition trigger caspase-1 dependent 
SREBP activation and cell survival. 
Aerolysin leads to the permeabilization of the plasma 
membrane to ions. Decrease in intracellular potassium 
triggers the assembly of both IPAF and NALP3 
inflammasomes, which allow the activation of caspase-1. 
Through a yet to be determined intermediate, caspase-1 
triggers export of SREBPs from the ER, and its 
subsequent proteolytic processing in the Golgi by S1P 
and S2P proteases. The released transcription factor 
migrates to the nucleus, where it activates genes 
harboring a Sterol Responsive Element (SRE) in their 
promoter. Lipid metabolic pathways are thus activated. 
This sequence of events contributes to cell survival. 
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Interestingly, whereas we show that a caspase can be an upstream activator 
of SREBPs, it has recently been found that caspases can also lie downstream of 
SREBPs [274]. The gene encoding for caspase-2 was indeed found to be a target of 
both SREBP2 [274] and SREBP1c [275]. These findings and the present study 
suggest a complex interplay between caspases and SREBPs, as well as between 
intracellular ion composition and lipid metabolism. These mechanisms are likely to be 
important to regulate lipid homeostasis in mammalian cells, both under physiological 
conditions and during disease. 
Finally, the present study, combined with recent findings in the literature, 
illustrates the complexity of the cellular response to pore formation by bacterial 
toxins. Major changes induced by membrane permeabilization include loss of 
transmembrane potential [90], massive entry of calcium [125, 135], osmotic stress 
[262] and efflux and influx of small ions along their respective gradients [90, 276]. 
Each of these events appears to trigger signaling pathways, some of which are 
aimed at warning the immune system, while others appear to promote death or 
survival of the attacked cell. For example, toxin-induced increases in cytosolic 
calcium were found to trigger activation of the NF-κB pathway [135, 277], whereas 
toxin-induced osmotic stress was found to activate p38 MAPK [262]. Interestingly, 
activation of p38 leads on one-hand to the release of chemokines such as IL-8 [262] 
and on the other, switches on a survival pathway, at least in none immune cells [138]. 
It indeed appears that, depending on the cell type, survival pathways will 
preferentially be triggered, whereas in others, in particular cells of the immune 
system, apoptotic pathways are rapidly switched on [116, 132, 278]. It will be of 
interest in the future to identify the full range of cellular changes that are sensed by 
pore-forming toxin treated cells, how the cells respond to them and how the balance 
between survival and death pathways is regulated. 
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Supplementary figure 1: A- Kinetics of aerolysin induced cell death. 
At time 0, CHO cells were incubated with 0.2 nM proaerolysin in tissue culture 
medium. At different times cells were harvested, stained with propidium iodide. 
Staining was quantified by FACS. Experiments were performed in triplicate. 
Errors represent standard deviations. B- Aerolysin induced change SREBP2 
mRNA. RNA differential display using the ADDER method was performed on CHO 
cells treated or not with 0.1nM proaerolysin for 1 or 3 hours, in duplicated 
samples. The 3hrs band indicated by the arrow was excised from the gel, 
processed for sequencing and the corresponding gene identified by a DNA blast 
search.  
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Supplumentary figure 2: Aerolysin induced activation of SREBP2 is 
not due to contaminating LPS, ER vacuolation or extracellular entry 
of calcium. A- To test whether aerolysin induced SREBP2 maturation could be 
due to contaminating LPS, we analyzed the effect of polymixin B (10 µg/ml), 
which did not inhibit SREBP2 activation. Moreover using a fluorescence reporter 
assay for IL-8 expression, we estimated the LPS contamination of our aerolysin 
samples to ≈ 15pg of LPS per mg of aerolysin. Altogether these observations show 
that SREBP2 activation is not due to contaminating LPS. B- CHO cells were 
incubated in culture medium complemented with 150 mM sucrose (that prevent 
aerolysin induced ER vacuolation, unpublished) and subsequently treated for 
different times with 0.2 nM proaerolysin. Membrane and nuclear fractions were 
prepared and analyzed (80 µg) for the presence of SREBP-2 by Western blotting. 
C- CHO cells were incubated in tissue culture medium with or without 5 mM 
EGTA. Cellular fractions were subsequently treated and analyzed as in B. SREBP2 
maturation is not inhibited by preventing either ER vacuolation or calcium entry. 
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Supplementary figure 3: Monensin leads to an increase in cellular 
sodium. CHO cells were treated for 3 hrs with or without proaerolysin (0.2 nM), 
Valinomycin (5 µM) or monensin (5 µM). Cells were then rapidly wash, lysed and 
the relative cellular content in sodium determined. As shown, monensin led to an 
increase in cellular sodium that was more pronounced than with proaerolysin. As 
expected valinomycin has little effect for cellular sodium, since its potassium 
specificity is well established. 
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Supplementary figure 4: Caspase activation by aerolysin. A- CHO cells 
were treated with proaerolysin (0.2 nM) for 3 hrs in the presence or absence of 
polymixin B (10 µg/ml). During the last hour, FLICACasp1was added to the culture 
medium. Cells were then washed and the number of FLICACasp1 positive cells 
determined by FACS analysis. B- CHO cells were treated with proaerolysin (0.2 
nM), valinomycin (5µM) or staurosporine  (1 µM) for 4hrs and caspase-3 activation 
was monitored using FLICACasp3.  
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Supplementary figure 5: Down regulation of inflammasome components 
by siRNA. A- HeLa cells were transiently transfected (24h) with RNAi duplexes 
against ASC, NALP3 and IPAF. The efficiency of the siRNA to reduce the 
corresponding messenger was measured by real time PCR. The messenger of Tata 
Binding protein (TBP) was used as a control. B- HeLa cells were transiently 
transfected (24h) or not with the following FLAG-tagged constructs: ASC, IPAF 
or NALP3 and co-transfected (24h) or not with RNAi duplexes against the 
corresponding protein. The effects of siRNAs on the protein levels were analyzed 
by Western blotting using an anti-FLAG antibody. Two duplex sequences, labeled 
1 and 2, were used for NALP3 and IPAF. 
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Supplementary figure 6: Inflammasome and caspase-1 activation. AB. 
HeLa cells were transfected in single to triple transfections with siRNAs against 
Nalp3, ASC, Ipaf, Caspase 3 (casp3), the G protein of the Vesicular Stomatitis 
virus (VSV-G), an irrelevant scramble RNA sequence (scrambled, 
5'GUGCGACUGCUGGAC UACU) or a negative control siRNA from Quiagen (Neg. 
Ctrl., UUC UCC GAA CGU GUC ACG U). A- Cells were then treated or not with 
proaerolysin for 3 h at 0.2 nM. During the last hour, FLICACasp1 was added to the 
medium. Cells were then washed and the number of FLICACasp1 positive cells 
determined by FACS analysis. B- Cells were treated for 1 min with 1nM 
proaerolysin and then incubated in tissue culture medium for 4h prior to 
propidium iodide staining. Propidium iodide positive cells were quantified by FACS 
analysis. 
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Supplementary figure 7: : Activation of interferon ß by Sendai Virus. 
Hela cells were transfected (24h) or not with RNAi duplexes against ASC and 
IPAF and then infected or not for an additional 24h with Sendai Virus. A, 
Activation the NF-kB pathway was monitored using a classical luciferase gene 
expression reporter assay. RNAi against ASC and Ipaf did not prevent NF-kB 
activation. The lower fold increase in gene expression is likely due to the toxicity 
of the RNAi (48h in total). B, Activation of the interferon pathway was also 
witnessed by the phosphorylation of interferon regulatory factor 3 (IRF3). 
 
 
 
 85 
 
 
 
 
 
 
Supplementary figure 8: Determination of the efficiency of RNAi by 
real-time PCR.  RNAi duplexes against SREBP1 or SREBP2 or SCAP or S1P or 
S2P were transiently transfected (48h) in HeLa cells. Real-time PCR were 
performed on the corresponding gene.  
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Supplementary figure 9: A- CHO cells were treated or not with 1µg /ml 25 
hydroxycholesterol (25OH Chol.) for 1h at 37°C. Cells were additionally treated or 
not with 0.2 nM proaerolysin for different times, still in the presence or not of 
25OH Chol. The intracellular potassium concentration was determined by flame 
photometry. B. CHO cells overexpressing INSIG-1 or treated with 25-hydroxy 
cholesterol (25-OH Chol) were treated with 0.2nM proaerolysin and caspase 1 
activation was determined using FLICACasp1 reagent. C- CHO cells were treated for 
1h with 25OH Chol. then treated with staurosporine at different concentration 
for an additional 4h prior to propidium iodide staining. Propidium iodide positive 
cells were quantified by FACS analysis. D- CHO cells were treated or not with 
leupeptin (250 µg/ml), bafilomycin (0.5µM) or 25-OH-Chol (1µg/ml) for 1h. Cells 
were then treated for 1 min with 1nM proaerolysin and then incubated in tissue 
culture medium for 4h in the presence of the corresponding drugs,  prior to 
propidium iodide staining. Propidium iodide positive cells were quantified by FACS 
analysis. Experiments were performed in triplicate. Errors represent standard 
deviations.  
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Supplementary figure 10 : HeLa cells transfected or not with different 
pCDNA3 plasmids for 48h. Cells were then treated for 1 min with 1nM 
proaerolysin and then incubated in tissue culture medium for 4h in the presence 
of the corresponding drugs, prior to propidium iodide staining. Propidium iodide 
positive cells were quantified by FACS analysis.  
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Supplementary figure 11: CHO cells were treated with cerulenin 20µg /ml 1h 
at 37°C, then for 1 min with proaerolysin at different concentration and and 
further incubated in tissue culture medium for 2h prior to propidium iodide 
staining and FACS analysis of PI positive cells. 
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EXPERIMENTAL PROCEDURE 
Cells,  reagents,  cholesterol and potassium 
determinations 
CHO and HeLa cells were grown as described [279]. Human fibroblasts were grown 
in a 15% FCS DMEM medium. SRD-12B cells (S1P-/-, [251]) and M19 cells (S2P-/-, 
[248]) deficient in the Site 1 and site 2 proteases respectively were obtained from J. 
Goldstein. Wild type and mutant aerolysins and Staphylococcus α-toxin were purified 
as described respectively [75, 280]. Cerulenin, valinomycin and 25-
hydroxycholesterol were purchased from Sigma, 19-hydroxycholesterol from 
Steraloids, FLICACasp1 (FLICA-YVAD-FMK) from Immunochemistry technologies, Ac-
YVAD-chloromethylketone from Bachem, siRNAs against S1P from Quiagen, against 
caspase-1, caspase-3, SCAP, S2P, SREBP1 and 2 from Santa Cruz. Anti-hamster 
SREBP2 monoclonal antibodies were form ATCC (Clones CRL-2198, Rockville, MD), 
and anti-human SREBP1 from Santa Cruz, HRP secondary antibodies from Pierce.  
Cellular potassium contents were determined by flame photometry using a Philips 
PYE UNICAM SP9 atomic absorption spectrophotometer as described [90]. 
Propidium iodide staining (2 µg /ml, Molecular Probes) was performed for 5min in the 
CO2 incubator. Cells are then analyzed by Fluorescence activated Cell Sorter 
(FACS). Cellular cholesterol was measured using the Ampex Red detection kit 
(Molecular Probes).  
Toxin treatment and subcellular fractionation 
Unless specified otherwise, cells were treated with 0.2 nM proaerolysin in tissue 
culture medium in the CO2 incubator. Low potassium medium refers to Hanks buffer 
(140 mM NaCl, 5 mM KCl, 10 mM Hepes, 1.3 mM CaCl2, 0.5 mM MgCl2, 0.36 mM 
K2HPO4, 0.44 mM KH2PO4, 5.5 mM D-glucose, 4.2 mM NaHCO3) and high potassium 
medium was identically with the exception of the NaCl (5 mM) and KCl 
concentrations (140 mM). Membrane and nuclear extracts were prepared as 
described [153]. 
 90 
RNA differential display and Real  time PCR 
CHO cells were treated or not with 0.1nM proaerolysin for 1 or 3 hours in tissue 
culture medium before RNA extraction. RNA differential display was performed 
according to the described ADDER method [261]. Upregulated messenger bands 
were extracted from the sequencing gels and processed for sequencing as described 
[261]. The corresponding genes were identified by BLASTn analysis. 
For real-time PCR, RNA was extracted from one confluent 10 cm-dish of HeLa cells 
treated or not with proaerolysin and transfected or not with siRNAs, using commercial 
RNA easy mini extraction kits (Quiagen). RNA was quantified by spectrometry and 1 
µg was used for reverse transcription using hexanucleotides (Roche). A 1/40 dilution 
of the cDNA was used to perform the real-time PCR using the Cyber Green reagent 
(Roche).  
Immunofluorescence 
CHO cells were fixed 15 min with paraformaldehyde 3%, permeabilized with saponin 
0.1% in PBS-BSA 0.5% for 5 min, labeled with anti-SREBP2 monoclonal antibodies 
followed by FITC-conjugated secondary antibodies (Molecular Probes). Images were 
acquired using a 100X lens on an Axiophot (Carl Zeiss Microimaging, Inc.), equipped 
with a Hamamastu cooled camera using the Openlab acquisition software. 
Plasmids,  RNAi duplexes and transfections 
The CMV-Insig-1-Myc plasmid was from ATCC (Clone 88099). Human ASC was 
cloned into the PCR3.V66-Met-FLAG mammalian expression vector, human IPAF in 
the pCR3.V62-Met-FLAG vector, human FLAG-NALP3 in the pCR3 vector and 
Caspase-1 in the pCDNA3 vector. HeLa cells were transfected with 1 µg cDNA/9.6 
cm2 plate using Fugene (Roche Diagnostics Corporation). The following RNAi 
duplexes were purchased from Quiagen: AACTGGACCTGCAAGGACTTG 
against ASC [281], AAGCTTCAGGTGTTGGAATTA and 
GCATGATCTCTCAGCAAAT against NALP3 and 
AACTGGGCTCCTCTGTAAATA and AAGTGCTCTGGACTTCATTAA against 
IPAF. For gene silencing, HeLa cells were transfected for 24 h with 200 pmoles/9.2 
cm2 dish of siRNA using Oligofectamine (Invitrogen) transfection reagent. The 
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transfection efficiency was >95% as witnessed using a fluorescent RNAi duplex 
against ASC. 
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Chapter3:         
Discussion 
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In this thesis, we present a novel pathway in which cells mount a defense towards 
pathogens that produce PFTs. Pore formation leads to potassium efflux and thus a 
decrease in the intracellular potassium concentration. This event is sensed by the 
inflammasome, which subsequently activates caspase-1. Caspase-1 in turn triggers 
the activation of SREBPs, the key regulators for lipid biosynthesis and uptake. 
Whereas our work has led to the identification of a new toxin triggered signaling 
pathway, it has clearly led to new questions. Some of the outstanding questions are: 
by how much, and for how long, must the intracellular potassium concentration drop 
for inflammasome assembly to occur? how is the decrease in intracellular potassium 
actually sensed? How does caspase-1 trigger SREBP activation? How does 
upregulation of metabolic genes promote cell survival? And finally is this pathway 
relevant to other situations of cellular stress or for normal cell physiology? 
 
 
Potassium sensing 
 
The starting event of this survival pathway is the potassium efflux that 
subsequently activates caspase-1. To determine the amplitude of the required 
potassium decrease, we “clamped” the aerolysin-induced potassium efflux by 
incubating CHO cells in media containing different concentrations of potassium from 
5mM (the normal extracellular potassium concentration) to 140mM (the normal 
cytoplasmic potassium concentration). Cells were treated with toxin for 4hrs. 
Caspase-1 activation, monitored using the fluorescent reagent FLICAcasp1, occurred 
as soon as the cytoplasmic potassium concentration dropped below 80mM (Fig. 3.1 
A). Similarly, a drop below 80 mM in intracellular potassium was required for SREBP 
activation (Fig. 3.1B) and the promotion of cell survival (Fig. 3.1C).  
Thus inflammasome activation and the downstream effects required 60 mM 
decrease in intracellular potassium. This threshold is certainly determined by a 
sensor, which could be the LRRs of the inflammasome components or some 
intermediate protein. 
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Preliminary data suggest the possible existence of an intermediate. We indeed 
found that aerolysin induced caspase-1 activation could be completely prevented by 
treating cells with specific inhibitors of phosphoinositide-3 kinase (PI3K), involved in 
the phosphorylation of phosphatidylinositols (Ptdlns) on position 3 of the inositol ring 
(not shown). Thus aerolysin-induced activation of the inflammasome is PI3K 
dependant. This observation raises the possibility that activation involves a 
membrane-localized event. This question can be addressed by studying the 
localization of the aerolysin induced inflammasome assembly by fluorescence 
microscopy using FLICAcasp1 reagent or a tagged caspase-1 and investigate whether 
PI3K plays a role in this localization. 
 
Figure 3. 0: Inflammasome activation and 
the downstream effects required 60 mM 
decrease in intracellular potassium.  
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 Alternatively, PI3K could modulate inflammasome activity by modifying one of 
its components. This point can be addressed by analyzing the phosphorylation status 
of inflammasome components. 
 
 
SREBP activation 
 
Caspase-1 activation within the inflammasome complex is a required and 
upstream event for SREBPs processing and nuclear translocation. However, we do 
not know how caspase-1 triggers SREBPs processing, although we demonstrate that 
caspase-1 does not directly cleave SREBPs. Intermediates can be found by different 
approaches such as performing a differential proteomics analysis. The protein 
contents of cells treated or not with aerolysin in the presence or absence of a 
caspase-1 inhibitor could be analyzed by 2D gel electrophoresis. Differentially 
expressed proteins could then be identified by mass spectrometry. An alternative 
approach to identify partners of caspase-1 involved in aerolysin-induced SREBPs 
maturation could be to use a more global strategy by performing a genome wide 
RNAi screen. Nuclear translocation of a fluorescent-tagged SREBP can be a read out 
followed by FACS analysis or automated fluorescence microscopy.  
Known substrates of caspase-1 are the pro-inflammatory cytokines IL-1β, IL-
18 [50] and IL-33 [51]. The maturation of IL-1β upon aerolysin treatment could occur 
in cells. However, production of IL-1β is usually attributed to cells of the immune 
system and not epithelial cells. 
Real-time PCR was performed on HeLa cells to determine whether they 
express IL-1β mRNA. As positive control, we used THP-1, a human acute monocytic 
leukemia cell line, which is widely used for studying inflammation. THP-1 were 
treated with vitamin D, an activation factor, that increases the level of IL-1β mRNA 
[282]. As expected, vitamin D increases to more than 20 fold the level of IL-1β mRNA 
in THP-1 (Fig 3.2). Somewhat surprisingly, Hela cells also produced IL-1β mRNA at a 
basal level at least 100 times lower that that of THP-1 cells (Fig 3.2). When treated 
for 5hrs with aerolysin, a 4 fold increase in IL-1β mRNA was observed (Fig 3.2). 
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Thus aerolysin induces increases of IL-1β mRNA in HeLa cells, to levels that 
however remain 50 fold below that observed for THP1 cells. We still have to 
investigate whether pro-IL-1β (the protein) is produced by HeLa cells and in that 
case, if aerolysin-induced caspase-1 activation could trigger the maturation release of 
IL-1β and whether it plays a role in aerolysin-induced SREBPs maturation. 
IL-1β is known to mediate its inflammatory effect after secretion in the 
extracellular medium and signaling through NF-κB activation. Another role of IL-1β 
can be in mediating communication between cells in a paracrine or autocrine fashion. 
Activation of NF-κB pathway can activate cell survival and proliferation in certain type 
of cells. IL-1β can in an autocrine way give a survival signal to the cell. To address 
the possible involvement of IL-1β in aerolysin induced SREBP activation, the 
presence of the IL-1β receptor should be demonstrated and the effects of inhibitory 
anti-IL-1β antibodies tested.  
Figure 3.2: Real-time PCR for quantification of the level of IL-1β 
mRNA in THP-1 activated or not and in HeLa cells treated or not 
with aerolysin 0.2nM for 3 or 5hrs. 
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A possibility that would be interesting to explore is whether cells that are 
harmed by aerolysin secrete a substance, which could be IL-1β, in order to warn 
neighboring cells allowing them to become, by some unknown means, more resistant 
to toxin action. For example, warned cells can be more resistant to attachment of the 
toxin or can already switched on the survival pathway. It has for example been shown 
that cells infected by Shigella flexineri communicate with neighboring via calcium 
waves propagated through connexin pores leading to inhibition of pathogen 
attachment at the cell surface of the warned cell [283]. It could be interesting to study 
the differences between naïve cells and warned cells in response to aerolysin – 
potassium efflux, caspase-1 activity, maturation of SREBPs and cell death - and the 
differences in kinetic of their responses. Warned cells can be prepared by 
transferring the culture medium of cells pulsed by aerolysin on new naïve cells.  
Another way of communication enlarging the view to a whole body infected by 
a PFT-producing bacteria is the endocrine communication. Aerolysin injury leads to 
activation of lipid synthesis by activating SREBPs. Lipids are the precursors of all 
steroids hormones, vitamins… that are important regulator in many metabolic 
pathways. Thus, production of lipids can be used in an endocrine communication by 
synthesizing steroids hormones. This can alert the whole body of the PFT injury to 
trigger a survival response. 
 
 
Cell survival 
 
SREBPs maturation induced by aerolysin delay cells death. However how 
SREBPs promote cell survival remains enigmatic. Considering the involvement of 
lipids, membrane repair mechanisms seem plausible. Indeed, the cell would trigger 
SREBPs maturation in a tentative of plasma membrane repair that could be efficient 
in certain cases such as for SLO or even Staphylococcal α-toxin injury. Plasma 
membrane repair and subsequent cell survival has been proposed by Valeva et al. in 
the case of staphylococcal α-toxin pore formation in fibroblast. This plasma 
membrane repair has been proposed to be dependant on lipid metabolism [294]. A 
good strategy to answer this question would be to perform a genome wide RNAi 
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screen and follow the cell viability by propidium iodide staining. Then candidates that 
lay downstream SREBPs activation should be investigate further. 
 
 
Pore-forming toxins trigger multiple signals in target 
cells 
 
Aerolysin induced caspase-1/SREBPs survival pathway is only one of the 
answer of the cell to that toxin injury. Many others exist and some has been already 
identified and some remains to be discovered.  
The first documented response of the cell to the formation of aerolysin channel 
was the activation of the G-proteins that led to the subsequent production of IP3 and 
release of calcium from the endoplasmic reticulum [125]. It is still unknown how 
aerolysin triggers activation of G-proteins.  
In addition to G-proteins, aerolysin triggers the activation of p38, ERK1/2 and 
JNK kinases signaling pathways [132], indicating that aerolysin activates three of the 
major MAPK signaling routes present in cells. Those MAPK signaling pathways are 
involved in cell proliferation, differentiation, apoptosis and inflammation. Interestingly, 
the first functional survival pathway discovered in response to aerolysin perforation 
has been shown to involve the p38 MAPK [138]. Toxin-induced osmotic stress has 
been found to trigger activation of p38 MAPK [262]. On the other hand, toxin-induced 
increases in cytosolic calcium were found to trigger activation of the NF-κB pathway 
[135, 277]. Interestingly, activation of p38 leads on one-hand to the release of 
chemokines such as IL-8 [262] and on the other hand, switches on a survival 
pathway, at least in none immune cells [138]. 
 
Finally, we did not only observed the aerolysin-induction of the caspase-
1/SREBPs survival pathway but we also found that aerolysin triggers increase of lipid 
droplets (my unpublished observations). 
Lipid droplets are metabolitically active lipid storage compartments. Lipid 
droplets are composed of a core rich in neutral lipids, fatty acids and cholesterol 
esters. One layer of phospholipids surrounds it. 
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We observed that bromoenol lactone (BEL), a specific inhibitor of the calcium-
independent phospholipase A2 (iPLA2) that catalyzes the release of fatty acid by 
phospholipids, inhibits aerolysin-induced lipid droplet formation, in epithelial cells. In 
parallel we observed that BEL leads to increase in aerolysin induced cell death (Fig 
3.3). These combined observations raise the possibility that lipid droplets are also 
involved in a cell survival pathway that would operate in parallel to the SREBP 
pathway. That these pathways are parallel pathways is indicated by the fact that 
aerolysin-induced lipid droplet formation is independent of caspase-1. Interestingly 
the initial triggering events is again the decrease of cellular potassium (Manuel 
Gonzalez, preliminary observations) 
Altogether it seems that in response to aerolysin cells triggers different 
signaling pathways, some of which are aimed at warning the immune system, while 
others appear to promote death or survival of the attacked cell.  
It will be greatly interesting to study the full range of pathway activation that is 
triggered in cells by a PFT. For that the global approach of genome wide RNAi 
screen following the cell viability by propidium iodide will be very helpful. 
 
 
 
 
 
 
Figure 3.3: Bromoenol lactone induces an increase in 
aerolysin-induced CHO cell death.  
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Cell type specificity of the response 
 
To add to this complexity of response to PFTs, it appears that depending on 
the cell type, survival pathways will be preferentially triggered, whereas in others, in 
particular cells of the immune system, apoptotic pathways are rapidly switched on 
[116, 132, 278]. We observed that 80% of RAW macrophages treated with a 5 times 
lower aerolysin concentration then that used on epithelial cells (0.04nM) die within 1 
hour (not shown). Epithelial cells express caspase-1 at very low levels compared to 
immune cells (caspase-1 is activated at least 100 time more in THP-1 than in CHO, 
not shown). Not surprisingly, the inflammasome is also less powerful for production of 
IL-1β in epithelial cells than in inflammatory cells, as seen in figure 3.2. The level of 
expression of the inflammasome and the level of active caspase-1 could account for 
the different responses triggered in response to PFTs. 
It will be interesting to understand how the balance between survival and 
death pathways is regulated. 
 
The caspase-1/SREBPs survival pathway has been described here in the 
context of infection by a PFT-producing pathogen. However in a more physiological 
context, it can be used in cells suffering a sudden potassium loss as a consequence 
of cell damage (organ lesion, organ arrest, ischemia…). Potassium channel are 
ubiquitously found in many cell types including neurons, cardiomyocytes, skeletal and 
smooth muscle cells, erythrocytes and pancreatic β cells. Numerous studies have 
implicated potassium channel function in the regulation of apoptosis and some have 
implicated them in survival [290]. For instance, treatment of neurons with diazodide, a 
KATP channel opener, protected the cells against cerebral ischemia [291], and amyloid 
β peptide toxicity [292], suggesting that activation of KATP channel might have a 
neuroprotective effect. Similar to neurons, increased KATP channel activity also 
protects against ischemic injury in cardiomyocytes [293].  
Those studies show that even if sometimes involved in promotion of cell death, 
potassium loss can be useful for the cell, triggering different survival pathways. 
Potassium efflux seems to be involved in very large and diverse mechanisms of cell 
survival and have a much broader role than only involved in the control of the resting 
membrane potential and the rate of repolarization after an action potential in excitable 
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cells. It will be of interest to determine whether under these various situations, the 
SREBP is activated and participates in cell survival. 
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Résumé  
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INTRODUCTION 
 
 
Les microorganismes pathogènes et en particulier les bactéries produisent 
souvent des toxines formant des pores (PFT) comme facteurs de virulence. Ces 
protéines sont soit des PFTs bonafide soit des composants du type III de l’appareil 
de sécrétion impliqué dans la perforation de la membrane plasmique de l’hôte 
permettant l’injection d’effecteurs bactériens nécessaires à l’infection. La taille de ces 
pores varie de 1 à 2 nm pour les PFTs tels que l’aérolysine d’Aeromonas hydrophila 
ou l’α-toxine de Staphylococcus aureus, jusqu’à 25 à 30nm pour les toxines 
dépendant du cholestérol tel que la pneumolysine ou la listeriolysine O. Selon la 
toxine, sa concentration et le type cellulaire, le sort de la cellule perforée peut varier : 
les deux cas extrêmes étant d’une part la lyse osmotique des érythrocytes, qui ne 
sont pas nécessairement les cibles physiologiques de ces toxines, et d’autre part la 
réparation membranaire complète avec survie cellulaire telle qu’observée à de faibles 
doses de certaines toxines. L’issue la plus courante in vitro est cependant la mort 
cellulaire, qui peut être apoptotique ou nécrotique, mais qui n’a généralement pas été 
caractérisée. Ces mécanismes cellulaires sont encore mal connus. 
Nous nous sommes intéressés à la compréhension des réponses cellulaires 
face aux PFTs et en particulier aux phénomènes de survie. Pour cela, nous avons 
utilisé comme prototype des PFTs, l’aérolysine puisqu’elle est très bien caractérisée 
et qu’une grande variété de mutants est disponible. La toxine est sécrétée par 
l’espèce Aeromonas comme un précurseur inactif appelée pro-aérolysine. La pro-
aérolysine doit être protéolytiquement processée par des enzymes digestives ou par 
des protéases de la famille des furines. Le précurseur et la toxine mature, lient tous 
deux spécifiquement les protéines possédant une ancre glycosylphosphatidylinositol 
(GPI) à la surface cellulaire. Une fois liée et processée, la toxine s’heptamérise en un 
anneau circulaire. Ce processus est promu par les radeaux lipidiques (rafts). 
L’oligomérisation conduit à l’exposition de surface hydrophobique permettant 
l’insertion membranaire. La formation de pore rend la membrane plasmique 
perméable aux petits ions mais pas aux protéines. Plusieurs effets cellulaires 
spécifiques sont observés après traitement à l’aérolysine tels que le relâchement de 
calcium par le réticulum endoplasmique (ER), la vacuolisation du ER et la production 
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de molécules pro-inflammatoires comme le facteur de nécrose tumoral α (TNFα), 
l’interleukine 1β, l’interleukin 6 et la prostaglandine E2. Nous avons montré que 
l’efflux de potassium intracellulaire due à l’aérolysine déclenche l’activation de la 
caspase-1. Cette « cysteine-protease » est produite comme un précurseur de 45KDa 
qui nécessite une autocatalyse pour son activation. L’autoprotéolyse dépend de la 
formation d’un large complexe multiprotéique oligomérique appellé inflammasome. 
Le rôle de l’inflammasome est de rapprocher deux molécules de caspase-1 afin de 
permettre son activation. Deux types d’inflammasome sont connus chacun d’eux 
comporteant des membres différents de récepteurs de pattern de reconnaissance 
intracellulaire qui sont les membres de la famille NLR (NACHT-LRR). Ces derniers 
sont typiquement composés de 3 domaines : un domaine Leucine Rich Repeat (LRR) 
qui est le domaine de liaison du ligand, un domaine NACHT qui est le domaine 
d’oligomérisation, et enfin un domaine d’interaction homotypique protéine-protéine C-
terminal. Ce dernier pouvant être soit un domaine CARD soit un domaine pyrine 
(PYD). Un certain nombre de stimulus d’activation de ces inflammasomes ont 
récemment été identifiés comme les cristaux d’acide urique associés à la goutte, à 
l’ARN bactérien, à l’ATP extracellulaire, à une toxine marine affectant les canaux 
calciques, la maitotoxine ou encore à la flagelline cytoplasmique. Les 
inflammasomes peuvent donc être vus comme des détecteurs intracellulaires de 
signaux de danger. Deux membres NLR peuvent induire l’activation de la caspase-1 : 
NALP et IPAF. Les analyses génomiques ont révélé 14 NALPs dans le génome 
humain. Parmi eux, NALP1 et NALP3 ont été les mieux caractérisés et sont 
impliqués dans l’activation de la caspase-1. L’interaction des NALPs avec la 
caspase-1 n’est pas directe et dépendant d’une proteine adaptatrice, ASC contenant 
à la fois un domaine CARD et un PYD. IPAF, pour qui une seule forme a été 
rapportée, s’associe directement avec la caspase-1 par son domaine CARD C-
terminal même si des interactions directes et indirectes avec ASC peuvent exister. 
Nous avons trouvé que l’efflux de potassium induit par l’aérolysine déclenche 
l’assemblage de l’inflammasome IPAF et NALP3, activant ainsi la caspase-1. Plus 
important, nous avons trouvé que la caspase-1 induit alors l’activation de régulateurs 
centraux pour la biogénèse des membranes, les « Sterol Regulatory Element Binding 
Protein » (SREBP). SREBPs, à son tour, promeut la survie cellulaire. Notre travail 
montre qu’en plus d’un rôle bien établi dans l’induction de l’inflammation par une 
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activation des précurseurs de l’interleukine 1β, 18 et 33, la caspase-1 exerce un rôle 
beaucoup plus large que celui précédemment anticipé et en particulier un lien entre 
la composition ionique et les voies métaboliques lipidiques. 
 
 
 
 
 
RESULTATS ET DISCUSSION 
 
 
La formation des pores par l ’aérolysine conduit à  l ’activation 
de SREBPs.  
Pour étudier la réponse cellulaire aux PFTs, nous avons effectué une analyse 
d’expression différentielle des RNA. Nous nous sommes placés dans des conditions 
de traitement de nos cellules CHO avec l’aérolysine permettant une exclusion du 
propidium iodide, un agent intercalant de l’ADN, pendant au moins 10 heures. Cette 
étude nous a permis d’identifier plusieurs gènes différentiellement exprimés et en 
particulier SREBP2 qui était sur-exprimé après 3 heures de traitement à la toxine. 
SREBPs sont des facteurs de transcription ancrés à la membrane du ER qui régulent 
l’expression des gènes possédant dans leur promoteur un élément de réponse aux 
stérols (SRE). Typiquement, ils sont impliqués dans la régulation de la biosynthèse 
du cholestérol et des acides gras. SREBPs sont localisés dans la membrane du ER 
et sont relâchés séquentiellement par protéolyse. Deux enzymes sont responsables 
de ce processus protéolytique, S1P et S2P, qui sont toutes deux transmembranaires 
et qui résident dans le Golgi. La coupure de SREBPs requiert le transport de la 
protéine du ER vers le Golgi. Cette étape est contrôlée par une protéine « escorte » 
SCAP. Chez l’humain et le hamster, on connaît 3 isoformes : SREBP-1c et -1a qui 
proviennent d’un même gène et SREBP2 qui provient d’un gène différent. SREBP1 
est impliqué plutôt dans la biosynthèse des acides gras tandis que SREBP2 est 
plutôt impliqué dans la biosynthèse et l’entrée du cholestérol et des lipides. Différents 
stimulus ont été montrés comme induisant l’activation de SREBPs tels que la 
déplétion en cholestérol, la déplétion du calcium du reticulum endoplasmique, des 
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facteurs de croissance, la signalisation par l’insuline, la phagocytose et les chocs 
hypotoniques. 
Le principal mécanisme de régulation de SREBPs étant au niveau protéique plutôt 
que transcriptionel, nous avons testé si l’aérolysine provoquait une activation de 
SREBPs. Par western blot sur des fractions nucléaires et membranaires d’extrait 
cellulaire traités à la toxine, nous avons observé une diminution de la forme 
membranaire (immature, 123KDa) en même temps qu’une augmentation de la forme 
nucléaire (mature, ≈60KDa). La migration de SREBPs vers le noyau a aussi été 
observée par immunofluorescence. Les deux formes (SREBP1 et 2) sont maturées et 
transportées dans le noyau après traitement à l’aérolysine. 
Pour confirmer la présence d’une forme nucléaire active de SREBPs dans le 
noyau, nous avons testé la régulation des gènes sous le contrôle de SREBPs par 
real-time PCR. Les enzymes HMGCoA et « fatty acid synthase » sont activées 
respectivement par SREBP2 et 1. Nous avons observé une augmentation des taux 
de ces deux mRNA après traitement à la toxine. De même, nous avons observé une 
augmentation des taux de cholestérol totaux de 25 à 30% après 3 à 5hrs de 
traitement à la toxine en accord avec le rôle des SREBPs. 
Ces résultats montrent que l’aérolysine déclenche l’activation de SREBPs et la 
surexpression des gènes sous le contrôle des SRE ainsi que l’augmentation du 
cholestérol cellulaire. 
 
La toxine induit un efflux de potassium qui déclenche 
l ’activation de SREBP2.  
Pour comprendre les mécanismes médiant l’activation de SREBPs par 
l’aérolysine, nous avons étudié si la formation des pores était requise en utilisant des 
mutants hémolytiquement inactifs de l’aérolysine : ASSP qui lie les protéines GPI 
mais qui est incapable de s’heptamériser et le Y221G qui à la fois lie les protéines 
GPI et s’heptamérise mais qui est incapable de s’insérer dans la membrane et de 
former un pore. Aucun de ces deux mutants n’est capable d’activer SREBP2, 
montrant ainsi la nécessité de la formation du pore pour l’activation du facteur de 
transcription. De même, d’autres PFTs comme l’α-toxine de S. aureus dans les 
cellules HeLa (les cellules CHO sont insensibles à l’α-toxine) sont capables d’activer 
SREBP2.  
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Nous avons testé si la vacuolisation du reticulum endoplasmique ou l’entrée 
d’ion calcium depuis le milieu extracellulaire ou la sortie de calcium du reticulum 
endoplasmique pouvait déclencher l’activation de SREBPs. En empêchant chacun de 
ces effets en utilisant respectivement du saccharose, de l’EGTA ou du BAPTA, 
l’activation de SREBPs due à la toxine n’est pas inhibée.  
En suite, nous avons testé si la sortie de potassium par les pores de 
l’aérolysine pouvait être le déclenchant. Pour cela, nous avons utilisé des milieux 
extracellulaires riches en potassium (même concentration que le milieu 
intracellulaire) ou pauvres en potassium (même concentration que le milieu 
extracellulaire). L’efflux de potassium due à la toxine est bloqué lorsqu’un milieu riche 
en potassium est utilisé. Le blocage de l’efflux de potassium engendre l’inhibition de 
l’activation de SREBP2, suggérant la nécessité de l’efflux de potassium. Nous avons 
finalement utilisé la valinomycine, un ionophore du potassium pour déterminer si le 
potassium suffisait à activer SREBP2. L’essai a été concluant. En revanche, en 
utilisant un ionophore du sodium, le monensin, nous n’avons pas pu observer 
d’activation de SREBP2, montrant que ce n’est pas la dépolarisation membranaire 
qui transmet l’activation de SREBP2. 
 
L ’aérolysine déclenche l ’activation de la caspase-1  par 
l ’ inflammasome.  
L’événement permettant le déclenchement de l’activation de SREBPs est la 
perte du calcium intracellulaire. L’efflux de potassium due à l’α-toxine de S. aureus, 
les ionophores du potassium ou l’activation des récepteurs P2X7 par l’ATP 
extracelullaire a été montré comme pouvant activer la caspase-1. Par conséquent, 
nous avons analysé les effets de l’aérolysine sur la casapase-1. L’activation de la 
caspase-1 a été observée uniquement lorsque la formation du pore était possible 
(WT). De plus, l’activation de la caspase-1 n’est observée que si l’efflux de potassium 
n’est pas inhibé. De même, la valinomycine déclenche l’activation de la caspase-1. 
L’aérolysine induit l’activation de la caspase-1 de façon spécifique puisque à des 
temps identiques, l’activation de la caspase-3 n’est pas observée.  
Pour déterminer si les inflammasomes étaient impliqués dans l’activation de la 
caspase-1 par l’efflux de potassium dû à l’aérolysine, nous avons utilisé des RNAi 
pour réduire l’expression de IPAF, NALP3 et/ou ASC. La réduction individuelle de 
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l’expression de ces protéines mène à une réduction de l’activation de la caspase-1 
de 30 à 50%. La réduction de l’expression de ASC avec NALP3 n’induit pas une 
diminution de l’activation de la caspase-1 plus conséquente. Par contre, une 
diminution de ASC avec IPAF (ou des 3 protéines), induit quasiment une abolition de 
l’activation de la caspase-1. 
Ces résultats montrent que l’activation de la caspase-1 en réponse à l’efflux 
de potassium due à la toxine passe par l’assemblage des deux types 
d’inflammasome, IPAF et NALP3. Ici, il est important de noter que l’efflux de 
potassium est le premier stimulus à utiliser les deux inflammasomes à la fois, 
suggérant que pour un stress aussi sévère, la nature a prévu une voie de secours. 
 
L ’activation de SREBP par l ’aérolysine est induite par la  
caspase-1.  
L’efflux de potassium induit par l’aérolysine déclenche à la fois l’activation de 
la caspase-1 et de SREBP2. Pour déterminer si ces évènements font partie de la 
même voie d’activation, nous avons observé si l’inhibition de l’activation de l’une 
avait une conséquence sur l’activation de l’autre. L’utilisation d’un inhibiteur 
spécifique de la caspase-1 (YVAD) bloque totalement la maturation de SREBP2 due 
à l’aérolysine. La maturation de SREBP2 est aussi inhibée par l’utilisation de RNAi 
contre NALP3, ASC ou IPAF ou également contre la caspase-1. Ceci montre que la 
caspase-1 se situe au-dessus de l’activation de SREBPs dans la séquence 
d’événements déclanchés par la toxine et qu’elle est requise pour l’activation de 
SREBPs. En accord avec ce modèle, l’inhibition de l’activation de SREBP2 n’a aucun 
effet sur l’activation de la caspase-1 suite au traitement avec la toxine. 
 
La caspase-1  déclenche l ’activation de SREBPs par S1P et S2P .  
Puisque la caspase-1 est une protéase et puisque l’activation de SREBPs 
implique une protéolyse, nous en avons conclu qu’une activation directe était 
possible. SREBP1 et 2 de hamster contiennent chacun un site potentiel de coupure 
par la caspase-1 dans la partie cytoplasmique N-terminale qui donnerait naissance à 
un fragment de 3KDa et 27KDa respectivement. Cependant, ces formes seraient 
inactives car ne contiendraient pas le fragment bHLH-Zip. De plus, ces formes de 
SREBPs contiennent de nombreux acides aspartiques qui pourraient être des sites 
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de coupure à la caspase-1, non conventionnels. Pour cela, nous avons comparé les 
différences de profil de migration des formes nucléaires de SREBP2 obtenues après 
traitement à l’aérolysine ou à la β-méthyl-cyclodextrine, une drogue extrayant le 
cholestérol des membranes. Sur un gel de haute résolution, aucune différence de 
profil n’a pu être observée. 
Pour s’assurer que les enzymes usuelles de coupure de SREBPs sont 
utilisées dans le cas de l’activation par l’aérolysine, nous avons utilisé des RNAi 
contre S1P, S2P ou SCAP. Diminuer l’expression d’une de ces enzymes ou de la 
protéine « escorte » conduit à inhiber la maturation de SREBPs due à l’aérolysine. 
De même l’utilisation de cellules mutantes, qui n’expriment plus S1P ou S2P par 
rapport à ces mêmes cellules recomplémentées montre que l’activation de SREBPs 
par l’aérolysine requière les protéines de la voie usuelle d’activation de SREBPs. 
La survie cellulaire est stimulée par l’activation de SREBPs induite par la 
toxine. Nous avons montré une nouvelle voie de signalisation liant la 
perméabilisation membranaire par une toxine à l’activation de gènes lipogéniques. 
Nous avons ensuite étudié si cette voie jouait un rôle dans la survie cellulaire. Pour 
cela, nous avons inhibées différentes étapes de l’activation de cette voie puis nous 
avons observé la mort cellulaire par l’utilisation du « propidium iodide » et analyse 
par FACS. 
L’efflux de potassium induit par la toxine a été inhibé en utilisant un milieu riche en 
potassium (même concentration de potassium qu’intracellulairement). L’activation de 
la caspase-1 a été inhibée soit en utilisant un inhibiteur de la caspase-1 soit en 
utilisant des RNAi soit contre les composants de l’inflammasome soit contre la 
caspase-1 elle-même. L’activation de SREBP2 a été bloquée en utilisant l’inhibiteur 
25-hydroxycholestérol, qui est un inhibiteur de l’activation de SREBPs bien connu, ou 
en sur-exprimant par transfection INSIG-1. INSIG-1 est une protéine à plusieurs 
domaines transmembranaires impliquée dans la rétention de SREBP2 dans le ER. 
Aussi, l’activation de SREBP2 a été bloquée en utilisant des RNAi contre la 
machinerie d’activation (S1P, S2P, SCAP) de SREBPs ou encore des RNAi 
directement contre SREBP1 ou 2. Finalement, nous avons testé l’effet de l’inhibition 
d’enzymes sur-exprimées par SREBPs comme par exemple, la « fatty acid 
synthase » en utilisant un inhibiteur spécifique, la cérulénine.  
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La mort cellulaire est augmentée quand les cellules sont traitées à l’aérolysine 
dans un milieu riche en potassium. La mort cellulaire est également augmentée 
quand les inflammasomes NALP3 ou IPAF sont inhibés par RNAi, alors que des 
RNAi contre des protéines qui ne sont pas d’intérêt dans cette voie ne provoquent 
pas d’augmentation de la mort cellulaire. Cependant, inhiber uniquement un seul des 
deux inflammasomes, cependant, n’a pas d’effet sur la mort cellulaire. Ce sont des 
conditions sous lesquelles l’activation de la caspase-1 n’est que seulement 
modérément réduite. De même, l’inhibition de la casapse-1 par le YVAD augmente 
aussi la mort cellulaire. 
Ensuite, nous avons inhibé l’activation de SREBPs avec le 25-
hydroxycholestérol. Cette drogue n’a pas d’effet sur les evènements situés au-
dessus dans la cascade d’activation comme, par exemple, sur la cinétique de 
formation du pore de l’aérolysine ou encore sur l’activation de la caspase-1. La mort 
cellulaire due au traitement à l’aérolysine est cependant fortement augmentée en 
présence de 25-hydroxycholestérol. 
La mort cellulaire n’est pourtant pas due à l’accumulation d’insultes toxiques 
pour la cellule puisqu’en présence de 19-hydroxycholestérol, l’activation de SREBPs 
par la toxine n’est pas inhibée. De même, l’inhibition de l’activation de SREBPs n’est 
pas observée en utilisant des inhibiteurs non-relevants dans cette cascade 
d’activation, comme la leupeptine qui inhibe les enzymes lysosomales ou encore la 
bafilomycine qui inhibe la pompe à proton vacuolaire ATPase. 
L’alternative au 25-hydroxycholesterol est la surexpression d’INSIG-1 qui 
inhibe l’activation de SREBP2 à la fois par la β-méthyl-cyclodextrine et par 
l’aérolysine. De même que le 25-hydroxycholesterol, la surexpression d’INSIG-1 n’a 
pas d’effet sur l’activation de la caspase-1 par l’aérolysine mais promeut la mort 
cellulaire. En revanche, la surexpression d’autres protéines non reliées à cette voie 
d’activation comme l’hémagglutinine transmembranaire d’influenza ou la « green 
fluorescente protein » (GFP), dans le même vecteur d’expression qu’INSIG-1, n’a 
aucun effet. Finalement, nous avons testé l’inhibition d’une enzyme sur-exprimée par 
SREBPs. Nous avons observé une mort cellulaire due à l’aérolysine accrue 
drastiquement quand la « fatty acid synthase » est inhibée par la cérulénine. 
 112 
Ensemble, ces résultats montrent que si l’on interfère avec l’activation de SREBPs 
ou avec sa fonction, cela promeut la mort cellulaire en réponse à la formation du pore 
par l’aérolysine. 
 
L ’activation de SREBPs due au déclenchement de l ’activation 
de la caspase-1  par Aeromonas  promeut la survie cellulaire.   
Pour tester si la voie d’activation de SREBPs dépendant de la caspase-1 
opère également durant une infection par une bactérie β-hémolytique, nous avons 
infecté des fibroblastes humains primaires par Aeromonas trota, une espèce 
produisant l’aérolysine et étant responsable de diarrhées chez les humains. La 
bactérie est capable de déclencher une activation massive de la caspase-1 de façon 
strictement dépendante de l’aérolysine. En effet, une souche bactérienne mutante, 
incompétente pour la production de l’aérolysine montre que la caspase-1 n’est pas 
activée. L’infection de ces cellules primaires avec la souche sauvage d’Aeromonas 
trota mène à une forte activation de SREBP2 tandis que la souche déficiente pour la 
production de l’aérolysine n’a aucun effet. Finalement, la souche sauvage 
d’Aeromonas trota mais pas la souche déficiente, induit la mort cellulaire et celle ci 
est augmentée si l’on traite les cellules avec l’inhibiteur de l’activation de SREBPs, le 
25-hydroxycholestérol. 
Ces résultats indiquent que pendant l’infection, la formation des pores de 
l’aérolysine mène à l’activation de la caspase-1, ce qui ensuite mène à l’activation et 
à la translocation de SREBPs dans le noyau et finalement l’activation de cette voie 
promeut la survie cellulaire. 
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Conclusion 
 
 
Nous avons identifié une voie de signalisation nouvelle qui lie un changement 
dans la composition ionique cytoplasmique due à la perméabilisation membranaire, 
au métabolisme lipidique et à la survie de la cellule. Bien que beaucoup de détails 
doivent encore être élucidés, nous avons montré que la réponse cellulaire à une 
chute en potassium intracellulaire induit une cascade d’événement: la chute de 
potassium intracellulaire active les inflammasomes IPAF et NALP3/ASC et permet 
l’activation protéolytique de la caspase-1. Il reste à déterminer si les senseurs directs 
de la chute de potassium intracellulaire est le domaine LRR de IPAF et NALP3 ou si 
un adaptateur est nécessaire. Une fois activée, la caspase-1 induit l’activation de 
SREBPs en agissant sur une cible intermédiaire qui induit alors l’activation de 
SREBPs par S1P et S2P. La forme mature de SREBPs est alors transportée dans le 
noyau ce qui conduit à la surexpression des gènes lipidiques. Tous les moyens que 
nous avons utilisés pour interférer avec l’activation de SREBPs ou avec la 
biosynthèse lipidique ont tous mené à l’augmentation de la mort cellulaire due à la 
toxine. Cela indique que la biosynthèse lipidique est importante pour la survie 
cellulaire en réponse à la formation d’un pore. 
La caspase-1 a, semble-t-il, un rôle beaucoup plus large que celui entrevu 
précédemment. En plus de son rôle bien connu dans la production de cytokines 
proinflammatoires et dans l’initiation de la mort cellulaire après infection par un 
certain nombre de pathogènes, la caspase-1 semble aussi être importante dans la 
promotion de la survie cellulaire, après infection ainsi que de jouer un rôle plus 
général, comme celui de régulateur positif du métabolisme lipidique. Ainsi, pour 
remplir toutes ses fonctions, la caspase-1 doit avoir des cibles autres que seulement 
les précurseurs des interleukines 1β, 18 et 33. L’identification des cibles de la 
caspase-1 reste à découvrir. 
Nous avons montré que l’activation d’une caspase était un élément activateur, 
précédant l’activation de SREBPs mais il a aussi récemment été montré que les 
caspases pouvaient se trouver en dessous de SREBPs. En effet, il a été montré que 
la caspase-2 est une cible de SREBP-2 et -1c. À la lumière de ces résultats, il 
semblerait que les voies des caspases et de SREBPs soient intimement liées. 
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La réponse cellulaire aux toxines bactériennes qui forment des pores est donc 
extrêmement complexe et beaucoup de travail reste à faire. Des changements 
majeurs apparaissent dans la cellule suite à la formation d’un pore par une PFT qui 
induisent tous des voies de signalisations différentes dont certaines ont pour but 
d’alarmer le système immunitaire alors que d’autres encouragent la mort ou la survie 
cellulaire de la cellule blessée. Dépendamment du type cellulaire, des voies 
conduisant à la survie ou à la mort seront activées préférentiellement. Dans les 
cellules immunitaires par exemple, les voies conduisant à la mort cellulaire sont 
rapidement activées. Dans le futur, il sera donc intéressant de comprendre comment 
ces équilibres sont gérés au sein des cellules et quels sont tous les effets sentis par 
des cellules traitées par des PFTs. 
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